11 March 2024
EMA/CHMP/57124/2024
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Minutes for the meeting on 22-25 January 2024

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

Health and safety information

In accordance with the Agency's health and safety policy, delegates have been briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. The meeting was held in-person.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the list of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

CHMP agenda for 22-25 January 2024.

The CHMP adopted the agenda.

1.3. Adoption of the minutes

CHMP minutes for 11-14 December 2023 plenary meeting.

The CHMP adopted the minutes for the 11-14 December 2023 plenary.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 15 January 2024.

The CHMP adopted the minutes from the PROM meeting held on 15 January 2024.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. Leniolisib - Orphan - EMEA/H/C/005927

Pharming Technologies B.V.; Treatment of activated phosphoinositide 3-kinase delta

syndrome (APDS)

Scope: Possible oral explanation

Action: Possible oral explanation to be held on 24 January 2024 at 16:00

List of Outstanding Issues adopted on 09.11.2023, 20.07.2023. List of Questions adopted on 24.01.2023.

The CHMP confirmed that an oral explanation was not needed at this time.

See 3.2

2.1.2. Masitinib - Orphan - EMEA/H/C/005897

AB Science; in combination with riluzole for the treatment of adult patients with amyotrophic lateral sclerosis (ALS)

Scope: Oral explanation

Action: Oral explanation to be held on 24 January 2024 at 14:00

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 15.12.2022.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

2.1.3. Dopamine hydrochloride - PUMA - EMEA/H/C/006044

Treatment of hypotension in neonates, infants and children

Scope: Oral explanation

Action: Oral explanation to be held on 23 January 2024 at 11:00

List of Outstanding Issues adopted on 12.10.2023. List of Questions adopted on 30.03.2023.

An oral explanation was held on 23 January 2024. The presentation by the applicant focused on clinical data.

See 3.2

2.1.4. Tofersen - Orphan - EMEA/H/C/005493

Biogen Netherlands B.V.; treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

Scope: Oral explanation

Action: Oral explanation to be held on 23 January 2024 at 14:00

List of Outstanding Issues adopted on 09.11.2023, 14.09.2023. List of Questions adopted on 30.03.2023.

The CHMP noted the third party interventions.

The CHMP agreed that an oral explanation was not needed at this time.

2.1.5. Danicopan - PRIME - Orphan - EMEA/H/C/005517

Alexion Europe; Treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria

Scope: Oral explanation

Action: Oral explanation to be held on 24 January 2024 at 09:00

List of Outstanding Issues adopted on 09.11.2023. List of Questions adopted on 20.07.2023.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

2.2. Re-examination procedure oral explanations

2.2.1. Translarna - ataluren - EMEA/H/C/002720/R/0071, Orphan

PTC Therapeutics International Limited

Re-examination Rapporteur: Kristina Dunder, Re-examination Co-Rapporteur: John Joseph Borg

Scope: Oral explanation

Action: Oral explanation to be held on 23 January 2024 at 16:00

Participation of patient representatives.

Opinion adopted on 14.09.2023. Request for Supplementary Information adopted on 25.05.2023.

An oral explanation was held on 23 January 2024. The presentation by the MAH focused on clinical data.

See 9.1

2.3. Post-authorisation procedure oral explanations

2.3.1. Prevenar 20 (previously named Apexxnar) - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0012

Pfizer Europe MA EEIG

Rapporteur: Daniela Philadelphy, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Jean-Michel Dogné

Scope: "Extension of indication to include infants, children and adolescents from 6 weeks to less than 18 years of age for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae, based on final results from studies B7471003, B7471011, B7471012, B7471013 and B7471014. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.0 of the RMP has also been submitted."

Scope: Oral explanation

Action: Oral explanation to be held on 22 January 2024 at 16:00

Request for Supplementary Information adopted on 14.12.2023, 12.10.2023, 20.07.2023, 30.03.2023.

An oral explanation was held on 22 January 2024. The presentation by the MAH focused on clinical data.

See 5.1

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. Exblifep - Cefepime / Enmetazobactam - EMEA/H/C/005431

Advanz Pharma Limited; treatment of: 1) complicated urinary tract infections (including pyelonephritis); 2) hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP); 3) patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above and 4) infections due to aerobic Gram-negative organisms in adults with limited treatment options

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 09.11.2023. List of Questions adopted on 25.05.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that enmetazobactam is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendations dated 25 January 2024.

The summary of opinion was circulated for information.

3.1.2. Nezglyal - leriglitazone - Orphan - EMEA/H/C/005757

Minoryx Therapeutics S.L.; the treatment of cerebral progression and myelopathy in male patients with adrenoleukodystrophy (ALD).

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 14.09.2023. List of Questions adopted on 15.12.2022.

The Committee adopted a negative opinion by consensus recommending the refusal of the granting of the conditional marketing authorisation. The CHMP assessment report was adopted.

The question-and-answer document was circulated for information.

3.1.3. Niapelf - Paliperidone - EMEA/H/C/006185

Neuraxpharm Pharmaceuticals S.L.; Treatment of schizophrenia

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Xeplion

List of Outstanding Issues adopted on 09.11.2023. List of Questions adopted on 25.05.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.4. Ryzneuta - Efbemalenograstim alfa - EMEA/H/C/005828

Evive Biotechnology Ireland Limited; Reduction in the duration of neutropenia and the incidence of febrile neutropenia.

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 21.07.2022. List of Questions adopted on 27.01.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that efbemalenograstim alfa is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 25 January 2024.

The summary of opinion was circulated for information.

3.1.5. Syfovre - Pegcetacoplan - EMEA/H/C/005954

Apellis Netherlands B.V.; Treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 12.10.2023. List of Questions adopted on 25.05.2023.

The CHMP noted the third party interventions.

The Committee adopted a negative opinion by consensus recommending the refusal of the granting of the marketing authorisation. The CHMP assessment report was adopted.

The question-and-answer document was circulated for information.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. Efanesoctocog alfa - Orphan - EMEA/H/C/005968

Swedish Orphan Biovitrum AB (publ); Treatment and prophylaxis of bleeding in patients with haemophilia A

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 14.09.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.2. Leniolisib - Orphan - EMEA/H/C/005927

Pharming Technologies B.V.; Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 09.11.2023, 20.07.2023. List of Questions adopted on 24.01.2023.

See 2.1

The Committee was reminded of the status of this application and its remaining outstanding issues.

The CHMP confirmed that an oral explanation was not needed at this time.

The Committee adopted a 3rd list of outstanding issues with a specific timetable.

3.2.3. Denosumab - EMEA/H/C/005964

treatment of osteoporosis

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 14.09.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.4. Masitinib - Orphan - EMEA/H/C/005897

AB Science; in combination with riluzole for the treatment of adult patients with amyotrophic lateral sclerosis (ALS)

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 15.12.2022.

See 2.1

The Committee was reminded of the status of this application and its remaining outstanding issues.

The CHMP confirmed that an oral explanation was not needed at this time.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.5. Dopamine hydrochloride - PUMA - EMEA/H/C/006044

Treatment of hypotension in neonates, infants and children

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 12.10.2023. List of Questions adopted on

30.03.2023.

See 2.1

The Committee was reminded of the status of this application and its remaining outstanding issues.

An oral explanation was held on 23 January 2024. The presentation by the applicant focused on clinical data.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.6. Danicopan - PRIME - Orphan - EMEA/H/C/005517

Alexion Europe; Treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 09.11.2023. List of Questions adopted on 20.07.2023.

See 2.1

The Committee was reminded of the status of this application and its remaining outstanding issues.

The CHMP agreed that an oral explanation was not needed at this time.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.7. Denosumab - EMEA/H/C/006378

prevention of skeletal related events with advanced malignancies

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 14.09.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. Aflibercept - EMEA/H/C/006150

treatment of age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO), due to diabetic macular oedema (DME) and due to myopic choroidal neovascularisation (myopic CNV)
or central RVO)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.2. Erdafitinib - EMEA/H/C/006050

treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.3. Insulin lispro - EMEA/H/C/006158

treatment of diabetes mellitus

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. Insulin aspart - EMEA/H/C/006187

treatment of diabetes mellitus

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.5. amino acids - Orphan - EMEA/H/C/005557

Recordati Rare Diseases; treatment of decompensation episodes in MSUD patients

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.6. Pomalidomide - EMEA/H/C/006273

treatment of adult patients with multiple myeloma

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.7. Pomalidomide - EMEA/H/C/006314

treatment of multiple myeloma

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.8. Pomalidomide - EMEA/H/C/006302

in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma (MM)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.9. Pomalidomide - EMEA/H/C/006294

treatment of adults with multiple myeloma

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.10. Imetelstat - Orphan - EMEA/H/C/006105

Geron Netherlands B.V.; for the treatment of transfusion-dependent anaemia in adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.11. Sotatercept - PRIME - Orphan - EMEA/H/C/005647

Merck Sharp & Dohme B.V.; treatment of pulmonary arterial hypertension in adults

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

The CHMP agreed to consult the CVS Working Party and adopted a list of questions to this group.

The CHMP agreed to revert to a standard timetable.

3.3.12. Ustekinumab - EMEA/H/C/005805

treatment of moderate to severe plaque psoriasis in adults, children and adolescents, active psoriatic arthritis in adults, treatment of Crohn’s Disease and Ulcerative colitis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. Dasatinib - EMEA/H/C/006251

Indicated for the treatment of chronic myelogenous leukaemia (CML)

Scope: Letter by the applicant dated 19 December 2023 requesting an extension to the clock stop to respond to the list of questions adopted in September 2023, which was agreed on 21.12.2023.

Action: For information

List of Questions adopted on 14.09.2023.

The CHMP noted the extension to the clock stop, which was adopted on 21.12.2023.

3.4.2. Meningococcal group A, B, C, W and Y vaccine - EMEA/H/C/006165

indicated for active immunisation to prevent invasive disease caused by Neisseria meningitidis groups A, B, C, W, and Y

Scope: Request by the applicant for an extension to the clock stop to respond to the list of questions adopted in October 2023, which was adopted via written procedure on 21.12.2023.

Action: For information

List of Questions adopted on 12.10.2023.

The CHMP noted the extension to the clock stop, which was adopted on 21.12.2023.

3.4.3. omecamtiv mecarbil - EMEA/H/C/006112

treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction less than 30%

Scope: Letter by the applicant dated 11.01.2024 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in December 2023.

Action: For adoption

List of outstanding issues adopted on 14.12.2023. List of Questions adopted on 26.04.2023.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in December 2023.

3.4.4. liquid ethanolic extract 30 per cent (W/W) of allium cepa fresh bulb and citrus limon fresh fruit / dry aqueous extract of paullinia cupana seed / dry hydroethanolic extract of theobroma cacao seed - EMEA/H/C/004155

treatment of alopecia areata in children and adolescents

Scope: Letter by the applicant dated 10.01.2024 requesting an extension to the clock stop to respond to the list of questions adopted in October 2023.

Action: For adoption

List of Questions adopted on 12.10.2023.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in October 2023.

3.4.5. Ustekinumab - EMEA/H/C/006221

treatment of active plaque psoriasis, Crohn’s disease, active ulcerative colitis and active psoriatic arthritis, treatment of plaque psoriasis

Scope: Letter by the applicant dated 18.01.2024 requesting an extension to the clock stop to respond to the list of questions adopted in November 2023.

Action: For adoption

List of Questions adopted on 09.11.2023.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in November 2023.

3.4.6. Levetiracetam - EMEA/H/C/006186

treatment of partial onset seizures

Scope: Letter by the applicant dated 22.01.2024 requesting an extension to the clock stop to respond to the list of questions adopted in November 2023.

Action: For adoption

List of Questions adopted on 09.11.2023.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in November 2023.

3.4.7. Serplulimab - Orphan - EMEA/H/C/006170

Henlius Europe GmbH; first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)

Scope: Letter by the applicant dated 19.01.2024 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in December 2023.

Action: For adoption

List of Outstanding Issues adopted on 14.12.2023. List of Questions adopted on 20.07.2023.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in December 2023.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

No items

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

No items

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Abilify Maintena - Aripiprazole - EMEA/H/C/002755/X/0045

Otsuka Pharmaceutical Netherlands B.V.

Rapporteur: Bruno Sepodes, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to introduce a new pharmaceutical form associated with two new strengths (720 and 960 mg Prolonged-release suspension for injection).
The RMP (version 12.1) is updated in accordance."

Action: For adoption

List of Questions adopted on 09.11.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

4.1.2. Opdivo - nivolumab - EMEA/H/C/003985/X/0132

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Martin Huber

Scope: quality

Action: For adoption

List of Outstanding Issues adopted on 14.12.2023. List of Questions adopted on 14.09.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

4.1.3. Tepadina - Thiotepa - EMEA/H/C/001046/X/0049

ADIENNE S.r.l. S.U.

Rapporteur: Alexandre Moreau

Scope: "Extension application to add a new strength (200 mg powder and solvent for solution for infusion)."

Action: For adoption

List of Questions adopted on 09.11.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

4.1.4. Uptravi - Selexipag - EMEA/H/C/003774/X/0038

Janssen-Cilag International N.V.

Rapporteur: Martina Weise, PRAC Rapporteur: Nathalie Gault

Scope: "Extension application to add a new strength of 100 µg film-coated tablets in HDPE bottle. The RMP (version 10.1) is updated in accordance."

Action: For adoption

List of Outstanding Issues adopted on 09.11.2023. List of Questions adopted on 22.06.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP adopted the similarity assessment report.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

No items

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Bimzelx - Bimekizumab - EMEA/H/C/005316/X/0021

UCB Pharma S.A.

Rapporteur: Finbarr Leacy, PRAC Rapporteur: Liana Martirosyan

Scope: "Extension application to add a new strength of 320 mg (160 mg/ml) for bimekizumab solution for injection in pre-filled syringe or pre-filled pen, for subcutaneous (SC) administration."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects and the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with

the list of questions.

4.3.2. Cresemba - Isavuconazole - Orphan - EMEA/H/C/002734/X/0042/G

Basilea Pharmaceutica Deutschland GmbH

Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension application to add a new strength of 40 mg hard capsule to be used in paediatric patients 6 years and older grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment of paediatric patients aged 1 year and older for CRESEMBA 200 mg powder, based on final results from studies 9766-CL-0107 and 9766-CL-0046. Study 9766-CL-0046 is a Phase 1, open-label, multicenter study to evaluate the PK, safety and tolerability of intravenous and oral isavuconazonium sulfate in paediatric patients. This study was conducted in two sequential parts: Part 1 with three intravenous dosing cohorts, and Part 2 with two oral dosing cohorts. Study 9766-CL-0107 is a Phase 2, open-label, non-comparative, multicenter study to evaluate the safety and tolerability, efficacy, and PK of isavuconazole for the treatment of invasive aspergillosis or mucormycosis in paediatric patients aged 1 to < 18 years.
As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 9.1 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application relating to quality and clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.3. Eurartesim - Piperaquine tetraphosphate / Artenimol - EMEA/H/C/001199/X/0041

Alfasigma S.p.A.

Rapporteur: Janet Koenig

Scope: "Extension application to introduce a new pharmaceutical form associated with 2 new strengths (80 mg/10 mg and 160 mg/20 mg dispersible tablets)."

Action: For adoption

The Committee discussed the issues identified in this application relating to quality, non-clinical and clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.4. Mektovi - Binimetinib - EMEA/H/C/004579/X/0029

Pierre Fabre Medicament

Rapporteur: Janet Koenig

Scope: "Extension application to add a new strength of 45 mg (film-coated tablets)."

Action: For adoption

The Committee discussed the issues identified in this application relating to quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.5. Ocrevus - Ocrelizumab - EMEA/H/C/004043/X/0039

Roche Registration GmbH

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Gabriele Maurer

Scope: "Extension application to introduce a new pharmaceutical form (solution for injection) associated with a new strength (920 mg) and new route of administration (subcutaneous use). The RMP (version 9.0) is updated in accordance."

Action: For adoption

The Committee discussed the issues identified in this application relating to quality and clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.6. PHEBURANE - Sodium phenylbutyrate - EMEA/H/C/002500/X/0037

Eurocept International B.V.

Rapporteur: Jayne Crowe, PRAC Rapporteur: Eamon O Murchu

Scope: "Extension application to introduce a new pharmaceutical form associated with a new strength (500 mg film-coated tablets). The RMP (version 1.1) is updated in accordance."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.7. Skyrizi - Risankizumab - EMEA/H/C/004759/X/0043/G

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Finbarr Leacy, PRAC Rapporteur: Liana Martirosyan

Scope: "Extension application to a new strength of 180 mg of risankizumab (solution for injection in cartridge) grouped with a type II variation extension of indication (C.I.6.a) to include treatment of adult patients with moderately to severely active ulcerative colitis, for SKYRIZI, based on final results from studies M16-067 substudy 2: a phase 2b/3 multicenter, randomized, double-blind, placebo-controlled induction study to evaluate the efficacy and safety of risankizumab in subjects with moderately to severely active ulcerative colitis, and M16-066 substudy 1: a multicenter, randomized, double-blind, placebo controlled 52-week maintenance and an open-label extension study of the efficacy and safety of risankizumab in subjects with ulcerative colitis, as well as DDI study M19-974. As

a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC for the Skyrizi 600 mg concentrate for solution for infusion, and sections 1, 2, 4.1, 4.2, 4.8, 5.1, 5.2, 5.3, 6.5 and 6.6 of the SmPC for the Skyrizi 360 mg solution for injection in cartridge are updated. The Annex II, Labelling and Package Leaflets are updated in accordance. Version 5.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Abecma - Idecabtagene vicleucel - Orphan - ATMP - EMEA/H/C/004662/II/0031

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Rune Kjeken, Co-Rapporteur: Heli Suila, CHMP Coordinators: Ingrid Wang and Johanna Lähteenvuo, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD-38 antibody and have demonstrated disease progression on the last therapy for Abecma (idecabtagene vicleucel, ide-cel), based on results from study BB2121-MM-003 (MM-003, KarMMa-3). This is a Phase 3, multicentre, randomised, open-label study to compare the efficacy and safety of ide-cel versus standard regimens in subjects with RRMM. As a consequence, sections 2.1, 2.2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 6.3, 6.4 and 6.6 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 3.0 of the RMP has also been submitted. Furthermore, the PI is brought in line with the Guideline on core SmPC, Labelling and Package Leaflet for advanced therapy medicinal products (ATMPs) containing

genetically modified cells.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 31.10.2023, 16.06.2023.

The CHMP was updated on discussions at the CAT.

The Committee confirmed that all issues previously identified in this application had been addressed.

Based on the draft opinion by CAT, the CHMP adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.2. Amyvid - Florbetapir (18F) - EMEA/H/C/002422/II/0046

Eli Lilly Nederland B.V.

Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication to include monitoring response to therapy for AMYVID, based on supporting literature. As a consequence, sections 4.1 and 4.4 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.1 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update section 4.8 of the SmPC to reflect the current clinical trial exposures to align it with the updated RMP."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.3. Prevenar 20 (previously named Apexxnar) - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0012

Pfizer Europe MA EEIG

Rapporteur: Daniela Philadelphy, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Jean-Michel Dogné

Scope: "Extension of indication to include infants, children and adolescents from 6 weeks to less than 18 years of age for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae, based on final results from studies B7471003, B7471011, B7471012, B7471013 and B7471014. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 14.12.2023, 12.10.2023, 20.07.2023, 30.03.2023.

See 2.3

An oral explanation was held on 22 January 2024. The presentation by the MAH focused on

clinical data.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.4. Aspaveli - Pegcetacoplan - Orphan - EMEA/H/C/005553/II/0011

Swedish Orphan Biovitrum AB (publ)

Rapporteur: Alexandre Moreau, Co-Rapporteur: Selma Arapovic Dzakula, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include treatment of adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) not previously treated with a complement inhibitor for ASPAVELI, based on final results from study APL2-308. This is a Phase III, randomized, open-label, comparator-controlled study that enrolled adult patients with PNH who had not been treated with a complement inhibitor. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 09.11.2023, 20.07.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.5. Beyfortus - Nirsevimab - EMEA/H/C/005304/II/0005

Sanofi Winthrop Industrie

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include treatment of children up to 24 months of age who remain vulnerable to severe Respiratory Syncytial Virus (RSV) disease through their second RSV season for BEYFORTUS, based on interim results from studies D5290C00005 and D5290C00008.
Study D5290C00005 (MEDLEY) is a Phase II/III, randomized, double-blind, placebo-controlled study to evaluate the safety of Beyfortus in high-risk children. Study D5290C00008 (MUSIC) is a Phase II, open-label, uncontrolled, single-dose study to evaluate the safety and tolerability, pharmacokinetics, and occurrence of antidrug antibody for Beyfortus in immunocompromised children ≤ 24 months of age.
As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 2.1 of the RMP has also been submitted.
In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 12.10.2023, 20.07.2023.

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

5.1.6. Bimzelx - Bimekizumab - EMEA/H/C/005316/II/0020

UCB Pharma S.A.

Rapporteur: Finbarr Leacy, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Liana Martirosyan

Scope: "Extension of indication to include treatment of moderate to severe hidradenitis suppurativa (HS) in adults, based on final results from study HS0003 (BE HEARD I) and study HS0004 (BE HEARD II). These are phase 3, randomized, double blind, placebo controlled, multicenter, pivotal studies evaluating the efficacy and safety of bimekizumab in study participants with moderate to severe HS. Further supportive data are based on the results of phase 2 study HS0001 and phase 3 currently ongoing open-label extension study HS0005. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 1.10 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.3."

Action: For adoption

Request for Supplementary Information adopted on 12.10.2023.

The Committee discussed the issues identified in this application relating to non-clinical and clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.7. Dupixent - Dupilumab - EMEA/H/C/004390/II/0079

Sanofi Winthrop Industrie

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Finbarr Leacy, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication for DUPIXENT to include treatment of adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) with type 2 inflammation on triple therapy or double therapy if inhaled corticosteroids (ICS) are contraindicated, based on final results from study EFC15804 (BOREAS); this is a phase 3, randomized, double blind, placebo-controlled, multi-center, parallel group, 52-week study to assess the efficacy, safety and tolerability of dupilumab in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) with type 2 inflammation. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.8. Keytruda - Pembrolizumab - EMEA/H/C/003820/II/0145

Merck Sharp & Dohme B.V.

Rapporteur: Paolo Gasparini, PRAC Rapporteur: Bianca Mulder

Scope: "Extension of indication to include in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy) the treatment of high-risk locally advanced cervical cancer in adults who have not received prior definitive therapy [Stage IB2-IIB (with node-positive disease) or Stage III-IVA based on FIGO 2014] for Keytruda, based on KEYNOTE-A18: A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer. As a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 44.1 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information.

The CHMP agreed to the request by the MAH for an extension to the clock stop to respond to the RSI.

5.1.9. Kinpeygo - Budesonide - Orphan - EMEA/H/C/005653/II/0008

STADA Arzneimittel AG

Rapporteur: Christian Gartner, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: "Extension of indication to slow kidney function decline in adults with primary immunoglobulin A (IgA) nephropathy (IgAN) for KINPEYGO, based on Part B of study NefIgArd (NEF-301), listed as the final specific obligation in the Annex II; this is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of oral Nefecon compared to matching placebo in patients with primary IgAN on a background of optimized RAS inhibitor therapy. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.10. Opdivo - Nivolumab - EMEA/H/C/003985/II/0137

Bristol-Myers Squibb Pharma EEIG

Co-Rapporteur: Peter Mol, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication to include in combination with cisplatin-based chemotherapy

the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma for OPDIVO, based on interim results from study CA209901 (CheckMate901); this is a Phase 3, open-label, randomized study of nivolumab combined with ipilimumab, or with standard of care chemotherapy, versus standard of care chemotherapy in participants with previously untreated unresectable or metastatic urothelial cancer. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 35.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.11. Retsevmo - Selpercatinib - EMEA/H/C/005375/II/0021

Eli Lilly Nederland B.V.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Bianca Mulder

Scope: "Extension of indication to include the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer in the first-line setting for RETSEVMO based on interim data from studies LIBRETTO-001 (LOXO-RET-17001) and LIBRETTO-121; LIBRETTO-001 is an open-label, multicentre, global Phase 1/2 study of selpercatinib in patients with RET-altered advanced solid tumours. LIBRETTO-121 is a Phase 1/2 study of selpercatinib in paediatric patients with advanced RET-altered solid or primary central nervous system tumours. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.2 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 09.11.2023, 20.07.2023, 30.03.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

5.1.12. Retsevmo - Selpercatinib - EMEA/H/C/005375/II/0022

Eli Lilly Nederland B.V.

Rapporteur: Alexandre Moreau, Co-Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Bianca Mulder

Scope: "Extension of indication for RETSEVMO to include the treatment of adults with advanced or metastatic RET fusion-positive solid tumours with disease progression on or after prior systemic therapies or who have no satisfactory therapeutic options, based on interim data from study LIBRETTO-001 (LOXO-RET-17001); LIBRETTO-001 is an open-label, multicentre, global Phase 1/2 study of selpercatinib in adult and adolescent patients

with advanced RET-altered tumours. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC."

Action: For adoption

Request for Supplementary Information adopted on 09.11.2023, 20.07.2023, 30.03.2023.

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a 4th request for supplementary information with a specific timetable.

5.1.13. Rybrevant - Amivantamab - EMEA/H/C/005454/II/0010

Janssen-Cilag International N.V.

Rapporteur: Filip Josephson, PRAC Rapporteur: Gabriele Maurer

Scope: "Extension of indication to include amivantamab in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations for RYBREVANT, based on the final results from study 61186372NSC3001 listed as a Specific Obligation in the Annex II of the Product Information; this is a global, open-label, randomized Phase 3 study of ACP compared to CP alone in participants with newly diagnosed, locally advanced or metastatic NSCLC characterised by EGFR exon 20ins. The primary objective of the PAPILLON study is to compare efficacy, as demonstrated by PFS, in participants treated with ACP versus CP alone. As a consequence, sections 4.1, 4.2, 4.8, 4.9, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update Annex II and Annex IV of the PI. Consequently, the MAH proposes a switch from marketing authorisation under exceptional circumstances to full marketing authorisation given the fulfilment of the SOB. As part of the application, the MAH also requests an extension of the market protection by one additional year.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects and the request for 1 year of market protection.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.14. Triumeq - Dolutegravir / Abacavir / Lamivudine - EMEA/H/C/002754/II/0116

ViiV Healthcare B.V.

Rapporteur: Filip Josephson, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication to include treatment of paediatric patients from 6 kg to less than 25 kg for Triumeq Dispersible Tablets, based on PK, safety and efficacy data observed in the final results of study 205860 (IMPAACT 2019), further supported by extrapolation to data generated in adults and additional data in paediatric patients with the single entities. IMPAACT 2019 is a Phase 1/2 open-label, multicenter, multiple dose study of

dolutegravir/lamivudine/abacavir fixed dose combination tablets in treatment-experienced and treatment-naïve HIV-1-infected children less than 12 years of age. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 22.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the PI."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.15. Wegovy - Semaglutide - EMEA/H/C/005422/II/0017

Novo Nordisk A/S

Rapporteur: Patrick Vrijlandt, Co-Rapporteur: Thalia Marie Estrup Blicher

Scope: "Extension of indication to include risk reduction of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and BMI ≥27 kg/m2 for WEGOVY, based on results from study EX9536-4388 (SELECT); this is a randomised, double-blind, placebo-controlled, trial comparing semaglutide 2.4 mg with placebo both administered s.c. once weekly in subjects with established cardiovascular disease and overweight or obesity. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. As part of the application the MAH is requesting a 1-year extension of the market protection.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.16. WS2463
Imfinzi - Durvalumab - EMEA/H/C/004771/WS2463/0063
Lynparza - Olaparib - EMEA/H/C/003726/WS2463/0066

AstraZeneca AB

Lead Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension of indication for Lynparza in combination with Imfinzi for the maintenance treatment of adult patients with newly diagnosed advanced or recurrent endometrial cancer following treatment with Imfinzi and platinum-based chemotherapy, based on results from pivotal Phase III study, D9311C00001 (DUO-E). This was a phase III, randomised, double-blind, placebo-controlled, multicentre study evaluating the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer. As a consequence, sections 4.1, 4.2, 4.4, 4,5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 30 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.17. WS2538
Braftovi - Encorafenib - EMEA/H/C/004580/WS2538/0034
Mektovi - Binimetinib - EMEA/H/C/004579/WS2538/0030

Pierre Fabre Medicament

Lead Rapporteur: Janet Koenig, PRAC Rapporteur: Rugile Pilviniene

Scope: "Extension of indication to include binimetinib in combination with encorafenib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation for MEKTOVI and BRAFTOVI based on results from study PHAROS (Study ARRAY-818-202) at the primary completion date; this is a Phase II, open-label, multicentre, non-comparative study (interventional). As a consequence, sections 4.1, 4.4, 4.8, 5.1, 5.2, 9 and 10 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection for MEKTOVI.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

No items

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics - initial consultation

6.3.1. In vitro diagnostic medical device - EMEA/H/D/006372

next generation sequencing (NGS) assay for tumour mutation profiling

Scope: Opinion

Action: For adoption

Companion Diagnostics (Article 48 (3), (4), (7), (8) of Regulation (EU) 2017/746)

Request for supplementary information adopted on 14.12.2023, 09.11.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report.

6.3.2. in vitro diagnostic medical device - EMEA/H/D/006341

detection of the anaplastic lymphoma kinase (ALK) protein

Scope: Opinion

Action: For adoption

Companion Diagnostics (Article 48 (3), (4), (7), (8) of Regulation (EU) 2017/746)

Request for supplementary information adopted on 14.12.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report.

6.4. Companion diagnostics – follow-up consultation

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. seladelpar – Orphan - H0004692

CymaBay Ireland, Ltd; Primary Biliary Cholangitis (PBC)

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information.

The CHMP adopted the recommendations for PRIME eligibility.

The individual outcomes are listed in the PRIME Monthly Report on the EMA website, in the PRIME homepage, under Outcome of eligibility section.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Translarna - ataluren - EMEA/H/C/002720/R/0071, Orphan

PTC Therapeutics International Limited

Re-examination Rapporteur: Kristina Dunder, Re-examination Co-Rapporteur: John Joseph Borg

Scope: Re-examination of the renewal of marketing authorisation

Action: For adoption

Opinion adopted on 14.09.2023. Request for Supplementary Information adopted on 25.05.2023.

Participation of patient representatives.

See 2.2

The CHMP noted the third party interventions.

An oral explanation was held on 23 January 2024. The presentation by the MAH focused on clinical data.

The CHMP adopted a negative opinion by consensus, recommending not to renew the conditional marketing authorisation in accordance with Article 6(3) of Regulation (EC) No 507/2006.

The CHMP adopted the assessment report.

The EMA public health communication was circulated for information.

9.1.2. Rapilysin – reteplase – EMEA/H/C/000105

Actavis Group PTC ehf.; treatment of suspected myocardial infarction

Rapporteur: Martina Weise, Co-Rapporteur: Thalia Marie Estrup Blicher

Scope: Withdrawal of marketing authorisation

Action: For information

The CHMP noted the withdrawal of marketing authorisation.

9.1.3. Sustiva – efavirenz – EMEA/H/C/000249

Bristol-Myers Squibb Pharma EEIG; treatment of HIV-1 infection

Rapporteur: Bruno Sepodes, Co-Rapporteur: Filip Josephson

Scope: Withdrawal of marketing authorisation

Action: For information

The CHMP noted the withdrawal of marketing authorisation.

9.1.4. Ibandronic acid Sandoz – ibandronic acid– EMEA/H/C/002367

Sandoz GmbH; prevention of skeletal events

Rapporteur: Thalia Marie Estrup Blicher

Scope: Withdrawal of marketing authorisation

Action: For information

The CHMP noted the withdrawal of marketing authorisation.

9.1.5. VidPrevtyn Beta - SARS-CoV-2, B.1.351 variant, prefusion Spike delta TM protein, recombinant - EMEA/H/C/005754

Sanofi Pasteur; active immunisation against COVID-19 disease

Rapporteur: Jan Mueller-Berghaus

Scope: Withdrawal of marketing authorisation

Action: For information

The CHMP noted the withdrawal of marketing authorisation.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

10.1.1. Ocaliva - obeticholic acid - EMEA/H/A-20/1531

Advanz Pharma Limited

Referral Rapporteur: Carolina Prieto Fernandez, Referral Co-Rapporteur: Paolo Gasparini

Scope: List of outstanding issues, timetable

Action: For adoption

The European Commission (EC) initiated a procedure under Article 20 of Regulation (EC) No 726/2004 and requested the Agency/CHMP to assess the benefit-risk balance of Ocaliva (obeticholic acid). The review was prompted by final study results raising concerns of a potential lack of efficacy and worsened safety profile. These findings need to be reviewed in the context of all available data and their potential impact on the benefit-risk of Ocaliva assessed.

The CHMP adopted a list of outstanding issues with a specific timetable.

CHMP list of outstanding issues: 25.01.2024

Submission of responses: 07.03.2024

Re-start of the procedure: 28.03.2024

Rapporteur/co-rapporteur joint assessment report(s) circulated to CHMP: 04.04.2024

Ad-hoc expert group meeting (AHEG): Date to be confirmed

Comments: 11.04.2024

Updated Rapporteur/co-rapporteur joint assessment report(s) circulated to CHMP: 17.04.2024

CHMP LoOI or opinion: April, 2024 CHMP

The CHMP agreed to consult an ad-hoc expert group and adopted a list of question to the experts.

10.1.2. Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/A20/0065

Orexigen Therapeutics Ireland Limited

Referral Rapporteur: Thalia Marie Estrup Blicher, Referral Co-Rapporteur: Daniela Philadelphy

Scope: Letter from MAH requesting clock-stop extension

Action: For adoption

The European Commission (EC) initiated a procedure under Article 20 of Regulation (EC) No 726/2004 and requested the Agency/CHMP to assess the benefit-risk balance of Mysimba (naltrexone/bupropion), taking into account any consequences from the failure to comply with the obligations laid down in the marketing authorisation.
This review of all available data on the potential long-term cardiovascular risk and its impact on the benefit-risk balance of Mysimba in its approved indication was considered needed in view of the remaining concern and lack of adequate study plan to address the uncertainty about this risk.

The CHMP agreed to the request by the MAH and adopted a new procedural timetable.

CHMP list of outstanding issues: 14.12.2023

Submission of responses: 13.03.2024

Re-start of the procedure: 28.03.2024

Rapporteur/co-rapporteur joint assessment report circulated to CHMP: 04.04.2024

Scientific Advisory Group meeting: Date to be confirmed

Comments: 11.04.2024

Updated Rapporteur/co-rapporteur joint assessment report circulated to CHMP: 17.04.2024

CHMP list of outstanding issues or CHMP opinion: April, 2024 CHMP

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

10.4.1. Ibuprofen NVT – ibuprofen - EMEA/H/A-29(4)/1533

Laboratorios Liconsa, S.A.

Referral Rapporteur: Vilma Petrikaite, Referral Co-Rapporteur: Maria Concepcion Prieto Yerro

Scope: List of questions

Action: For adoption

Mutual Recognition Procedure number: LT/H/0162/002/E/001, notification sent by the Agency of Lithuania dated 17 November 2023 notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC.

The CHMP adopted a list of questions with a procedural timetable.

CHMP list of questions: January 2024 CHMP

Submission of responses: 01.02.2024

Re-start of the procedure: 06.02.2024

Rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 08.02.2024

Comments: 13.02.2024

Updated Rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 15.02.2024

CHMP opinion: February 2024 CHMP

10.4.2. Micrazym – porcine pancreas enzymes - EMEA/H/A-29(4)/1535

Avva Pharmaceuticals Ltd.

Referral Rapporteur: Patrick Vrijlandt, Referral Co-Rapporteur: Martina Weise

Scope: Appointment of Rapporteurs, list of questions, timetable

Action: For adoption

Decentralised Procedure number: NL/H/5258/001-002/DC, notification sent by the Agency of The Netherlands dated 21 December 2023 notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC.

The CHMP appointed Patrick Vrijlandt as referral rapporteur and Martina Weise as referral Co-Rapporteur. The Spanish NCA will support the Co-Rapporteur assessment.

The CHMP adopted a list of questions with a procedural timetable.

Start of procedure (CHMP): January, 2024 CHMP

List of Questions: 25.01. 2024

Submission of responses: 16.02.2024

Re-start of the procedure: 22.02.2024

Rapporteur/co-rapporteur assessment reports circulated to CHMP: 07.03.2024

Comments: 12 March 2024

Updated Rapporteur/co-rapporteur assessment reports circulated to CHMP: 14 March 2024

CHMP list of outstanding issues or CHMP opinion: March, 2024 CHMP

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

10.6.1. Pseudoephedrine – pseudoephedrine - EMA/H/A-31/1526

MAH various (NAPs + 1 CAP)

PRAC Rapporteur: Eva Jirsová, PRAC Co-Rapporteur: Maia Uusküla

Scope: Opinion

Action: For adoption

Review of the benefit-risk balance following notification by France of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data; PRAC recommendation.

Having considered the PRAC recommendation, the CHMP adopted an opinion by majority (31 out of 32 votes), recommending that the marketing authorisations for pseudoephedrine-containing medicinal products should be varied.

The divergent position (Alexandre Moreau) was appended to the opinion.

The EMA public health communication was circulated for information.

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

10.7.1. Synapse Labs Pvt. Ltd. – various – EMEA/H/A-31/1529

Various MAHs

Re-examination Referral Rapporteur: TBC, Re-examination Referral Co-Rapporteur: TBC

Scope: appointment of re-examination rapporteurs

Action: For adoption

Article 31 procedure triggered by the Agency of Medicines and Medical Devices (AEMPS) in Spain, concerning the contract research organisation (CRO) Synapse Labs Pvt. Ltd., located in Kharadi, Pune, India.

The CHMP noted the call for re-examination rapporteurs.

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

January 2024 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

The CHMP noted the information.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. Vote by proxy

The co-opted member Sol Ruiz gave a proxy to Maria Concepcion Prieto Yerro for the whole meeting and the Polish member Ewa B Iskra gave a proxy to Bruno Sepodes for the last three hours of the meeting on Thursday.

14.1.2. CHMP membership

No items

14.1.3. CHMP co-opted membership

The 3-year co-opted member mandate for Carla Torre comes to an end on 21.02.2024. Her area of expertise is Pharmaco-Epidemiology; especially for methodology (bias, effect modifications etc.) and interpretation of data, in particular study designs (observational studies, RWD etc.), strengths and weaknesses.

The 3-year co-opted member mandate for Blanka Hirschlerova comes to an end on 18.03.2024. Her area of expertise is Quality (non-biologicals) and pharmacokinetics.

The nomination procedure foresees that the CHMP should decide on their areas of expertise in order to proceed with the nominations.

The election for both positions is anticipated at the February 2024 plenary meeting.

Action: For endorsement

The CHMP agreed on the areas of expertise:

Position 1: Quality (non-biologicals)

Position 2: Expertise in Pharmacoepidemiology; especially for methodological analysis and interpretation of data in particular study designs*

**The Experience in Pharmacoepidemiology should be applied to regulatory decision-making processes. The interpretation of data in particular study designs should include strengths and weaknesses (observational studies, RWD from different sources).*

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for January 2024

Action: For adoption

The CHMP adopted the EURD list.

14.2.2. Paediatric Committee (PDCO)

Agenda of the January 2024 PDCO plenary meeting

Action: For information

The CHMP noted the PDCO agenda.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sean Barry, Vice-Chair: Francesca Luciani

Reports from BWP January 2024 meeting to CHMP for adoption:

- 10 reports on products in scientific advice and protocol assistance
- 9 reports on products in pre-authorisation procedures
- 3 reports on products in plasma master file

Action: For adoption

The CHMP adopted the BWP reports.

14.3.2. Nomination of members of BWP

Chair: Sean Barry, Vice-Chair: Francesca Luciani

Following the call for nominations launched in December for two new BWP members, the Quality Domain governance has recommended the new BWP members to be endorsed by CHMP.

Nomination(s) received

Action: For endorsement

The CHMP endorsed Sarah Gilgunn and Sonia Klingers as new BWP members.

14.3.3. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

Report from the SAWP meeting held on 08-11 January 2024. Table of conclusions

Action: For information

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

The CHMP noted the update.

14.3.4. Concept Paper for the development of a Reflection Paper on a tailored clinical approach in biosimilar development

Concept paper on tailored clinical approach in biosimilar development

Action: For adoption

The CHMP adopted the concept paper.

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

No items

14.9. Others

14.9.1. CHMP Learnings

CHMP: Outi Mäki-Ikola

Collection, discussion and recording of CHMP learnings.

Action: For information

The CHMP noted the information.

15. Any other business

15.1. AOB topic

15.1.1. OPEN update

List of products under the OPEN framework.

Action: For information

The CHMP endorsed the list of products under the OPEN framework.

List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 22-25 January 2024 CHMP meeting, which was held in-person.

An asterisk (*) after the role, in the second column, signals that the member/alternate attended remotely. Additional experts participated in (part of) the meeting, either in person or remotely.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Daniela Philadelphy	Member	Austria	No interests declared	
Christian Gartner	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate*	Belgium	No interests declared	
Lyubina Racheva Todorova	Member	Bulgaria	No interests declared	
Gergana Lazarova	Alternate*	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Emilia Mavrokordatou	Alternate	Cyprus	No restrictions applicable to this meeting	
Tomas Radimersky	Member*	Czechia	No interests declared	
Petr Vrbata	Alternate	Czechia	No interests declared	
Thalia Marie Estrup Blicher	Member	Denmark	No interests declared	
Aaron Sosa Mejia	Alternate*	Denmark	No participation in final deliberations and voting on:	Wegovy - Semaglutide - EMEA/H/C/005422 /II/0017
Alar Irs	Member*	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvuo	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate*	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate*	Germany	No interests declared	
Konstantina Alexopoulou	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Robert Porszasz	Member	Hungary	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Beata Maria Jakline Ullrich	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Member	Iceland	No interests declared	
Hjalti Kristinsson	Alternate*	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Finbarr Leacy	Alternate	Ireland	No interests declared	
Paolo Gasparini	Member*	Italy	No interests declared	
Maria Grazia Evandri	Alternate	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Vilma Petrikaite	Member	Lithuania	No interests declared	
Larisa Gorobets	Alternate	Lithuania	No restrictions applicable to this meeting	
Martine Trauffler	Member	Luxembourg	No interests declared	
John Joseph Borg	Member	Malta	No interests declared	
Peter Mol	Member	Netherlands	No interests declared	
Patrick Vrijlandt	Alternate	Netherlands	No interests declared	
Ingrid Wang	Member	Norway	No interests declared	
Eva Skovlund	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No restrictions applicable to this meeting	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Frantisek Drafi	Member	Slovakia	No interests declared	
Jana Klimasová	Alternate*	Slovakia	No restrictions applicable to this meeting	
Kristina Nadrah	Member	Slovenia	No participation in final deliberations and voting on:	Pomalidomide - EMEA/H/C/006314
Andreja Kranjc	Alternate*	Slovenia	No interests declared	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Carolina Prieto Fernandez	Alternate *	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate*	Sweden	No interests declared	
Bruno Delafont	Co-opted member	France	No interests declared	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member*	Spain	No interests declared	
Susanne Høpner Rasmussen	Expert	Denmark	No interests declared	
Melanie Diane Klok	Expert	Netherlands	No interests declared	
Paula Contreras Alarcón	Expert	Spain	No participation in discussion, final	Skyrizi - Risankizumab -

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
			deliberations and voting on:	EMEA/H/C/004759 /X/0043/G
Johanna de Groot	Expert	Netherlands	No interests declared	
Cristel Loeb	Expert	Netherlands	No interests declared	
Susan Uiterwaal	Expert	Netherlands	No interests declared	
Sabine Mayrhofer	Expert	Germany	No interests declared	
Maia Uusküla	Expert	Estonia	No interests declared	
Stefan Bonné	Expert	Belgium	No interests declared	
Rune Kjeken	Expert	Norway	No restrictions applicable to this meeting	
Nina Hessvik	Expert	Norway	No interests declared	
Lena Eroukhmanoff	Expert	Norway	No participation in discussion, final deliberations and voting on:	Bimzelx - Bimekizumab - EMEA/H/C/005316 /II/0020 EMEA/H/C/005316 /X/0021
Fabrice Eroukhmanoff	Expert	Norway	No interests declared	
Jutta Dedorath	Expert	Finland	No interests declared	
Riitta Niittyvuopio	Expert	Finland	No restrictions applicable to this meeting	
Karri Penttilä	Expert	Finland	No interests declared	
Eva Jirsová	Expert	Czechia	No interests declared	
Jana Lukacisinova	Expert	Czechia	No interests declared	
Michaela Dlouhá	Expert	Czechia	No interests declared	
Bojana Divkovic	Expert	Austria	No interests declared	
Elisabeth Wischnitzki	Expert	Austria	No interests declared	
Maximilian Koblischke	Expert	Austria	No participation in discussion, final deliberations and voting on:	Rybrevant - Amivantamab - EMEA/H/C/005454 /II/0010 Erdafitinib - EMEA/H/C/006050 Uptravi - Selexipag - EMEA/H/C/003774 /X/0038
Mirjam Hinterleitner	Expert	Austria	No interests declared	
Lisa Nika	Expert	Austria	No restrictions applicable to this meeting	
Harald Bernsteiner	Expert	Austria	No interests declared	
Benita Cullen	Expert	Ireland	No interests declared	
Sinead Harrington	Expert	Ireland	No interests declared	
Niamh Ennis	Expert	Ireland	No interests declared	
Emma Fagan	Expert	Ireland	No interests declared	
Agnieszka Przybyszewska	Expert	Ireland	No interests declared	
Olive Smyth	Expert	Ireland	No restrictions applicable to this meeting	
Brian Aylward	Expert	Ireland	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Ailise Carleton	Expert	Ireland	No interests declared	
Catherine Byrne	Expert	Ireland	No interests declared	
Larissa Higgins	Expert	Ireland	No interests declared	
Paolo Foggi	Expert	Italy	No interests declared	
Pierre Demolis	Expert	France	No interests declared	
Kristian Wennmalm	Expert	Sweden	No interests declared	
Mette Linnert Jensen	Expert	Denmark	No interests declared	
Brigitte Schwarzer-Daum	Expert	Austria	No interests declared	
Elina Rönnemaa	Expert	Sweden	No interests declared	
Rosalía Ruano Camps	Expert	Spain	No interests declared	
André Elferink	Expert	Netherlands	No interests declared	
Joerg Zinserling	Expert	Germany	No interests declared	
Susanne Poley-Ochmann	Expert	Germany	No interests declared	
Robert Pollmann	Expert	Germany	No interests declared	
Friederike Marei Feldmann	Expert	Germany	No interests declared	
Franziska Wolter	Expert	Germany	No interests declared	
Clemens Mittmann	Expert	Germany	No interests declared	
Sofia Kapanadze	Expert	Germany	No restrictions applicable to this meeting	
Georgios Aislaitner	Expert	Germany	No interests declared	
Marion Haberkamp	Expert	Germany	No interests declared	
Susanna Hausmann	Expert	Germany	No interests declared	
Martin Mengel	Expert	Germany	No interests declared	
Jo-Birger Schmeing	Expert	Germany	No restrictions applicable to this meeting	
Benjamin Micallef	Expert	Malta	No interests declared	
Melanie Ramberger	Expert	Spain	No interests declared	
Susanne Urach	Expert	Spain	No interests declared	
Illiana Meurs	Expert	Netherlands	No interests declared	
Mogens Westergaard	Expert	Denmark	No interests declared	
Martijn van Gils	Expert	Netherlands	No interests declared	
Miki Hew	Expert	Netherlands	No interests declared	
Mario Miguel Coelho da Silva Rosa	Expert	Portugal	No interests declared	
Antonio Gomez-Outes	Expert	Spain	No interests declared	
A representative from the European Commission attended the meeting.				
Observers from MHLW/PMDA (Japan) and FDA (USA) attended the meeting.				
Meeting run with the help of EMA staff.				

Experts were evaluated against the agenda topics or activities they participated in.

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

11 March 2024
EMA/CHMP/38321/2024

Annex to 22-25 January 2024 CHMP Minutes

Pre-submission and post-authorisations issues

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for January 2024: **For adoption**	Adopted

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for January 2024: **For adoption**	Adopted

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Bylvay - Odevixibat - EMEA/H/C/004691/S/0016, Orphan Albireo, Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Adam Przybylkowski	Positive Opinion adopted by consensus together with the CHMP assessment report. The Marketing Authorisation remains under exceptional circumstances.
Myalepta - Metreleptin - EMEA/H/C/004218/S/0035, Orphan Amryt Pharmaceuticals DAC, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Adam Przybylkowski	Positive Opinion adopted by consensus together with the CHMP assessment report. The Marketing Authorisation remains under exceptional circumstances.
Zokinvy - Lonafarnib - EMEA/H/C/005271/S/0008, Orphan EigerBio Europe Limited, Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Adam Przybylkowski	Positive Opinion adopted by consensus together with the CHMP assessment report. The Marketing Authorisation remains under exceptional circumstances.

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Ambrisentan Mylan - Ambrisentan - EMEA/H/C/004985/R/0009	Positive Opinion adopted by consensus together with the CHMP assessment report and

Mylan Pharmaceuticals Limited, Generic, Generic of Volibris, Rapporteur: Anastasia Mountaki, PRAC Rapporteur: Maria del Pilar Rayon Request for Supplementary Information adopted on 14.12.2023.	translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Cufence - Trientine - EMEA/H/C/004111/R/0016 Univar Solutions BV, Rapporteur: Daniela Philadelphy, Co-Rapporteur: Konstantina Alexopoulou, PRAC Rapporteur: Ana Sofia Diniz Martins Request for Supplementary Information adopted on 25.01.2024.	Request for supplementary information adopted with a specific timetable.
Dovato - Dolutegravir / Lamivudine - EMEA/H/C/004909/R/0045 ViiV Healthcare B.V., Rapporteur: Filip Josephson, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: David Olsen	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Giapreza - Angiotensin II - EMEA/H/C/004930/R/0027 Paion Deutschland GmbH, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Bianca Mulder Request for Supplementary Information adopted on 25.01.2024.	Request for supplementary information adopted with a specific timetable.
LysaKare - L-lysine hydrochloride / L-arginine hydrochloride - EMEA/H/C/004541/R/0016 Advanced Accelerator Applications, Rapporteur: Janet Koenig, Co-Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Adam Przybylkowski Request for Supplementary Information adopted on 25.01.2024.	Request for supplementary information adopted with a specific timetable.
Sixmo - Buprenorphine - EMEA/H/C/004743/R/0017 L. Molteni & C. dei Fratelli Alitti Societa di Esercizio S.p.A., Rapporteur: Finbarr Leacy, Co-Rapporteur: Petr Vrbata, PRAC Rapporteur: Adam Przybylkowski	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Striascan - Ioflupane (123I) - EMEA/H/C/004745/R/0012	Positive Opinion adopted by consensus together with the CHMP assessment report and

CIS BIO International, Generic, Generic of DaTSCAN, Rapporteur: Ewa Balkowiec Iskra, Co-Rapporteur: Simona Badoi, PRAC Rapporteur: Tiphaine Vaillant	translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Talzenna - Talazoparib - EMEA/H/C/004674/R/0017 Pfizer Europe MA EEIG, Rapporteur: Filip Josephson, Co-Rapporteur: Hrefna Gudmundsdottir, PRAC Rapporteur: Carla Torre Request for Supplementary Information adopted on 25.01.2024.	Request for supplementary information adopted with a specific timetable.
Ultomiris - Ravulizumab - EMEA/H/C/004954/R/0040 Alexion Europe SAS, Rapporteur: Carolina Prieto Fernandez, Co-Rapporteur: Robert Porszasz, PRAC Rapporteur: Kimmo Jaakkola Request for Supplementary Information adopted on 25.01.2024.	Request for supplementary information adopted with a specific timetable.
Xromi - Hydroxycarbamide - EMEA/H/C/004837/R/0023 Nova Laboratories Ireland Limited, Rapporteur: Anastasia Mountaki, PRAC Rapporteur: Jo Robays Request for Supplementary Information adopted on 25.01.2024.	Request for supplementary information adopted with a specific timetable.

B.2.3. Renewals of Conditional Marketing Authorisations

CARVYKTI - Ciltacabtagene autoleucel - EMEA/H/C/005095/R/0025, Orphan, ATMP Janssen-Cilag International NV, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Marcos Timón, CHMP Coordinator: Jan Mueller-Berghaus, PRAC Rapporteur: Jo Robays	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Lorviqua - Lorlatinib - EMEA/H/C/004646/R/0031 Pfizer Europe MA EEIG, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Nikica Mirošević Skvrce	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.

Ondexxya - Andexanet alfa - EMEA/H/C/004108/R/0041 AstraZeneca AB, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Bianca Mulder	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Translarna - Ataluren - EMEA/H/C/002720/R/0071, Orphan PTC Therapeutics International Limited, Re-examination: Kristina Dunder, Re-examination Co-Rapporteur: John Jospeh Borg, PRAC Rapporteur: Liana Martirosyan Opinion adopted on 14.09.2023. Request for Supplementary Information adopted on 25.05.2023.	See 2.3 and 9.1 The CHMP adopted a negative opinion by consensus, recommending not to renew the conditional marketing authorisation in accordance with Article 6(3) of Regulation (EC) No 507/2006.
WAYLIVRA - Volanesorsen - EMEA/H/C/004538/R/0026, Orphan Akcea Therapeutics Ireland Limited, Rapporteur: Patrick Vrijlandt, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Martin Huber Request for Supplementary Information adopted on 14.12.2023.	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its January 2024 meeting:	
EMEA/H/C/PSUSA/00001369/202304 (fentanyl (transmucosal route of administration)) CAPS: **Effentora** (EMEA/H/C/000833) (Fentanyl), Teva B.V., Rapporteur: Janet Koenig **Instanyl** (EMEA/H/C/000959) (Fentanyl), Takeda Pharma A/S, Rapporteur: Alexandre Moreau **PecFent** (EMEA/H/C/001164) (Fentanyl), Kyowa Kirin Holdings B.V., Rapporteur: Janet Koenig NAPS: **NAPs** - EUR PRAC Rapporteur: Tiphaine Vaillant, "30/04/2020 To: 30/04/2023"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s): Update of sections 4.2, 4.4 and 4.8 of the SmPC to inform prescribers about Opioid Use Disorder (OUD). The Package Leaflet is updated accordingly. Update of section 4.4 of the SmPC to add requirement regarding safe storage space. The Package Leaflet is updated accordingly. Update of SmPC section 4.9 to add toxic

	leukoencephalopathy as possible symptom of fentanyl overdose. The Package Leaflet is updated accordingly.
EMEA/H/C/PSUSA/00001465/202305 (follitropin beta) CAPS: **Puregon** (EMEA/H/C/000086) (Follitropin beta), Organon N.V., Rapporteur: Finbarr Leacy, PRAC Rapporteur: Rhea Fitzgerald, "01/05/2020 To: 01/05/2023"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reaction "anaphylactic reaction" with a frequency not known. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00002833/202304 (sunitinib) CAPS: **Sutent** (EMEA/H/C/000687) (Sunitinib), Pfizer Europe MA EEIG, Rapporteur: Paolo Gasparini, PRAC Rapporteur: Amelia Cupelli, "01/05/2020 To: 30/04/2023"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add the adverse reaction Hyperammonaemic encephalopathy with a frequency unknown and add a warning regarding Hyperammonaemic encephalopathy. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010262/202305 (trametinib) CAPS: **Mekinist** (EMEA/H/C/002643) (Trametinib), Novartis Europharm Limited, Rapporteur: Peter Mol, PRAC Rapporteur: David Olsen, "30/05/2022 To: 29/05/2023"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reaction AV block with a frequency " not known" for mono therapy and "uncommon" for combination therapy with dabrafenib, and include a footnote with the information; xx Including atrioventricular block complete. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010455/202305 (lumacaftor / ivacaftor) CAPS: **Orkambi** (EMEA/H/C/003954) (Lumacaftor /	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended,

Ivacaftor), Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Paolo Gasparini, PRAC Rapporteur: Eamon O Murchu, "20/05/2022 To: 19/05/2023"	recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add "depression" as an adverse drug reaction with a frequency not known and introduce a warning to inform prescribers about the risk of depression. The package leaflet is updated accordingly. Update of section 4.6 of the SmPC to amend wording regarding breast-feeding. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010535/202305 (ixazomib) CAPS: **NINLARO** (EMEA/H/C/003844) (Ixazomib), Takeda Pharma A/S, Rapporteur: Paolo Gasparini, PRAC Rapporteur: Ulla Wändel Liminga, "19/11/2022 To: 19/05/2023"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add the adverse reactions TEN, anaphylactic reaction and angioedema (frequency Rare) and a warning/precaution regarding TEN. The text should be further revised, as outlined below. The Package leaflet is updated accordingly, in addition to include previously missing symptoms for SJS/TEN.
EMEA/H/C/PSUSA/00010550/202305 (mycophenolate mofetil, mycophenolic acid) CAPS: **CellCept** (EMEA/H/C/000082) (Mycophenolate mofetil), Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher **Myclausen** (EMEA/H/C/001218) (Mycophenolate mofetil), Passauer Pharma GmbH, Rapporteur: Christian Gartner **Mycophenolate mofetil Teva** (EMEA/H/C/000882) (Mycophenolate mofetil), Teva B.V., Rapporteur: Petr Vrbata **Myfenax** (EMEA/H/C/000884) (Mycophenolate mofetil), Teva B.V., Rapporteur: Petr Vrbata NAPS: **NAPs** - EU, PRAC Rapporteur: Karin Erneholm, "02/05/2021 To: 02/05/2023"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s): Update of section 4.6 of the SmPC to amend the wording regarding breastfeeding. No update of the package leaflet is considered warranted as the current information is considered sufficient.
EMEA/H/C/PSUSA/00010671/202305 (semaglutide) CAPS: **Ozempic** (EMEA/H/C/004174) (Semaglutide),	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended

Novo Nordisk A/S, Rapporteur: Patrick Vrijlandt **Rybelsus** (EMEA/H/C/004953) (Semaglutide), Novo Nordisk A/S, Rapporteur: Patrick Vrijlandt **Wegovy** (EMEA/H/C/005422) (Semaglutide), Novo Nordisk A/S, Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Mari Thorn, "01/06/2022 To: 31/05/2023"	recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.5 and 4.8 of the SmPC to add the adverse reaction intestinal obstruction with a frequency not known and an interaction regarding other coumarin derivatives. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010717/202306 (binimetinib) CAPS: **Mektovi** (EMEA/H/C/004579) (Binimetinib), Pierre Fabre Medicament, Rapporteur: Janet Koenig, PRAC Rapporteur: Carla Torre, "26/06/2022 To: 26/06/2023"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add the adverse reaction Tumour lysis syndrome with a frequency not known and a warning/precaution regarding Tumour lysis syndrome. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010719/202306 (encorafenib) CAPS: **Braftovi** (EMEA/H/C/004580) (Encorafenib), Pierre Fabre Medicament, Rapporteur: Janet Koenig, PRAC Rapporteur: Rugile Pilviniene, "26/06/2022 To: 26/06/2023"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add the adverse reaction Tumour lysis syndrome with a frequency not known and a warning/precaution regarding Tumour lysis syndrome. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010848/202305 (onasemnogene abeparvovec) CAPS: **Zolgensma** (EMEA/H/C/004750) (Onasemnogene abeparvovec), Novartis Europharm Limited, Rapporteur: Emmely de Vries, CHMP Coordinator: Peter Mol, PRAC Rapporteur: Ulla Wändel Liminga, "24/05/2022 To: 23/05/2023"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to inform about an increased risk of AST and/or ALT elevation and thrombocytopenia observed in study in children weighing $\geqslant$ 8,5 kg to $\leqslant$ 21 kg (aged approximately 1.5 to 9 years) compared with

	studies in children < 8.5 kg. Update of sections 4.4 and 4.8 to reflect the fact that thrombocytopenia may occur within 3 weeks of administration. The package leaflet as well as Annex II, key elements for the patient information pack are amended accordingly. Update of section 4.8 to update the frequency of TMA and acute hepatic failure to "uncommon". The package leaflet is amended accordingly.
EMEA/H/C/PSUSA/00010852/202305 (ozanimod) CAPS: **Zeposia** (EMEA/H/C/004835) (Ozanimod), Bristol-Myers Squibb Pharma EEIG, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maria del Pilar Rayon, "20/11/2022 To: 19/05/2023"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product, concerning the following change(s): In view of available data on the important potential risk(s) – severe liver injury from spontaneous reports, the PRAC Rapporteur concluded that the product information of products containing ozanimod should be amended accordingly.
EMEA/H/C/PSUSA/00010897/202306 (elasomeran (Spikevax), elasomeran / imelasomeran (Spikevax bivalent Original/Omicron BA.1), elasomeran / davesomeran (Spikevax bivalent Original/Omicron BA.4-5)) CAPS: **Spikevax** (EMEA/H/C/005791) (COVID-19 mRNA vaccine (nucleoside-modified)), Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen, "18/12/2022 To: 17/06/2023"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation for the above mentioned medicinal product, concerning the following change: Update of section 4.8 of the SmPC to add the adverse reaction 'Chronic urticaria' with a frequency 'Not known'. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010907/202306 (fenfluramine) CAPS: **Fintepla** (EMEA/H/C/003933) (Fenfluramine), UCB Pharma SA, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, "25/12/2022 To: 24/06/2023"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.4 to amend the warning regarding VHD and PAH and update of section 4.8 to add the adverse reaction PAH with frequency not known, as well as the description of selected adverse reactions. The PL and Annex IID – additional risk minimisation measures are

	updated accordingly. Update of section 4.8 to add aggression with frequency common to the ADR table for LGS. The PL is updated accordingly.
EMEA/H/C/PSUSA/00010999/202306 (mosunetuzumab) CAPS: **Lunsumio** (EMEA/H/C/005680) (Mosunetuzumab), Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ulla Wändel Liminga, "02/12/2022 To: 02/06/2023"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation for the above-mentioned medicinal product, concerning the following changes: Update of sections 4.4 and 4.8 of the SmPC to add the adverse reaction haemophagocytic lymphohistiocytosis with a frequency 'uncommon' (both for all cases, and grade 3-4, based on review of available cases) and a warning/precaution regarding haemophagocytic lymphohistiocytosis. The package leaflet is updated accordingly.

B.4. EPARs / WPARs

Arpraziquantel - Arpraziquantel - EMEA/H/W/004252, Article 58 Merck Europe B.V., treatment of schistosomiasis in children, Known active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Casgevy - Exagamglogene autotemcel - EMEA/H/C/005763, Orphan, ATMP Vertex Pharmaceuticals (Ireland) Limited, treatment of transfusion-dependent β-thalassemia and sickle cell disease, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Dabigatran Etexilate Leon Farma - Dabigatran etexilate - EMEA/H/C/005922 Laboratorios Leon Farma S.A., prevention of venous thromboembolic events, Generic, Generic of Pradaxa, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Ibuprofen Gen.Orph - Ibuprofen - EMEA/H/C/006129 Gen.Orph, Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age, Generic, Generic of Pedea, Generic application (Article 10(1) of Directive No	For information only. Comments can be sent to the PL in case necessary.

2001/83/EC)	
Mevlyq - Eribulin - EMEA/H/C/006134 YES Pharmaceutical Development Services GmbH, treatment of breast cancer and liposarcoma, Generic, Generic of Halaven, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Pomalidomide Viatris - Pomalidomide - EMEA/H/C/006195 Viatris Limited, in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma (MM), Generic, Generic of Imnovid, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
SKYCLARYS - Omaveloxolone - EMEA/H/C/006084, Orphan Reata Ireland Limited, treatment of Friedreich's ataxia, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
VELSIPITY - Etrasimod - EMEA/H/C/006007 Pfizer Europe MA EEIG, treatment of patients with moderately to severely active ulcerative colitis (UC), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

Adenuric - Febuxostat - EMEA/H/C/000777/II/0071/G Menarini International Operations Luxembourg S.A., Rapporteur: Christian Gartner Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
Adtralza - Tralokinumab - EMEA/H/C/005255/II/0014/G LEO Pharma A/S, Rapporteur: Jayne Crowe Request for Supplementary Information adopted on 18.01.2024.	Request for supplementary information adopted with a specific timetable.
Artesunate Amivas - Artesunate - EMEA/H/C/005550/II/0011, Orphan	Positive Opinion adopted by consensus on

Amivas Ireland Limited, Rapporteur: Jayne Crowe Opinion adopted on 11.01.2024.	11.01.2024.
ASPAVELI - Pegcetacoplan - EMEA/H/C/005553/II/0015, Orphan Swedish Orphan Biovitrum AB (publ), Rapporteur: Alexandre Moreau Request for Supplementary Information adopted on 25.01.2024.	Request for supplementary information adopted with a specific timetable.
Benepali - Etanercept - EMEA/H/C/004007/II/0078 Samsung Bioepis NL B.V., Rapporteur: Christian Gartner Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.
BIMERVAX - Selvacovatein - EMEA/H/C/006058/II/0007/G Hipra Human Health S.L., Rapporteur: Beata Maria Jakline Ullrich Request for Supplementary Information adopted on 18.01.2024, 16.11.2023, 05.10.2023.	Request for supplementary information adopted with a specific timetable.
Briumvi - Ublituximab - EMEA/H/C/005914/II/0006 Neuraxpharm Pharmaceuticals S.L., Rapporteur: Ewa Balkowiec Iskra Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.
Cancidas - Caspofungin - EMEA/H/C/000379/II/0083/G Merck Sharp & Dohme B.V., Rapporteur: Christophe Focke Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
Cervarix - Human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) - EMEA/H/C/000721/II/0126/G GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.
Clopidogrel Viatris - Clopidogrel - EMEA/H/C/001189/II/0049/G Viatris Limited, Generic, Duplicate, Generic of Plavix, Duplicate of Grepid, Rapporteur: Kristina Nadrah Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
COMIRNATY - COVID-19 mRNA vaccine	Positive Opinion adopted by consensus on

(nucleoside-modified) - EMEA/H/C/005735/II/0197/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 11.01.2024.	11.01.2024.
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0202 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Request for Supplementary Information adopted on 25.01.2024.	Request for supplementary information adopted with a specific timetable.
Cosentyx - Secukinumab - EMEA/H/C/003729/II/0110 Novartis Europharm Limited, Rapporteur: Outi Mäki-Ikola Opinion adopted on 25.01.2024.	Positive Opinion adopted by consensus on 25.01.2024.
Ebixa - Memantine / Memantine hydrochloride - EMEA/H/C/000463/II/0101 H. Lundbeck A/S, Duplicate, Duplicate of Axura, Rapporteur: Maria Concepcion Prieto Yerro Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
EXPAREL liposomal - Bupivacaine - EMEA/H/C/004586/II/0018 Pacira Ireland Limited, Rapporteur: Elita Poplavska Request for Supplementary Information adopted on 25.01.2024.	Request for supplementary information adopted with a specific timetable.
Flucelvax Tetra - Influenza vaccine (surface antigen, inactivated, prepared in cell cultures) - EMEA/H/C/004814/II/0044 Seqirus Netherlands B.V., Rapporteur: Sol Ruiz Request for Supplementary Information adopted on 18.01.2024.	Request for supplementary information adopted with a specific timetable.
Foclivia - Pandemic Influenza vaccine (surface antigen, inactivated, adjuvanted) - EMEA/H/C/001208/II/0084/G Seqirus S.r.l, Rapporteur: Maria Grazia Evandri Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
Gliolan - 5-aminolevulinic acid - EMEA/H/C/000744/II/0026/G Photonamic GmbH & Co. KG, Rapporteur: Bruno Sepodes	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 11.01.2024.	
IVF Media G5 Series - Human albumin solution - EMEA/H/D/000003/II/0008 Vitrolife Sweden AB, Rapporteur: Filip Josephson Opinion adopted on 25.01.2024. Request for Supplementary Information adopted on 12.10.2023.	Positive Opinion adopted by consensus on 25.01.2024.
Kadcyla - Trastuzumab emtansine - EMEA/H/C/002389/II/0069/G Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 05.10.2023, 13.07.2023.	Positive Opinion adopted by consensus on 11.01.2024.
MINJUVI - Tafasitamab - EMEA/H/C/005436/II/0014/G, Orphan Incyte Biosciences Distribution B.V., Rapporteur: Aaron Sosa Mejia Request for Supplementary Information adopted on 25.01.2024.	Request for supplementary information adopted with a specific timetable.
Nimenrix - Meningococcal group A, C, W135 and Y conjugate vaccine - EMEA/H/C/002226/II/0130/G Pfizer Europe MA EEIG, Rapporteur: Ingrid Wang Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
Nulojix - Belatacept - EMEA/H/C/002098/II/0090/G Bristol-Myers Squibb Pharma EEIG, Rapporteur: Filip Josephson Request for Supplementary Information adopted on 18.01.2024.	Request for supplementary information adopted with a specific timetable.
Ovitrelle - Choriogonadotropin alfa - EMEA/H/C/000320/II/0090 Merck Europe B.V., Rapporteur: Patrick Vrijlandt Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.
Pemetrexed Fresenius Kabi - Pemetrexed - EMEA/H/C/003895/II/0035/G Fresenius Kabi Deutschland GmbH, Generic, Generic of Alimta, Rapporteur: Eva Skovlund Opinion adopted on 18.01.2024.	Positive Opinion adopted by consensus on 18.01.2024.
Polivy - Polatuzumab vedotin - EMEA/H/C/004870/II/0026, Orphan	Positive Opinion adopted by consensus on 11.01.2024.

Roche Registration GmbH, Rapporteur: Alexandre Moreau Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 16.11.2023.	
Posaconazole Accord - Posaconazole - EMEA/H/C/005005/II/0012/G Accord Healthcare S.L.U., Generic, Generic of Noxafil, Rapporteur: Hrefna Gudmundsdottir Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
PREVYMIS - Letermovir - EMEA/H/C/004536/II/0036, Orphan Merck Sharp & Dohme B.V., Rapporteur: Filip Josephson Request for Supplementary Information adopted on 25.01.2024.	Request for supplementary information adopted with a specific timetable.
Refixia - Nonacog beta pegol - EMEA/H/C/004178/II/0036/G Novo Nordisk A/S, Rapporteur: Daniela Philadelphy Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.
Skytrofa - Lonapegsomatropin - EMEA/H/C/005367/II/0019/G, Orphan Ascendis Pharma Endocrinology Division A/S, Rapporteur: Patrick Vrijlandt Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 12.10.2023.	Positive Opinion adopted by consensus on 11.01.2024.
Somavert - Pegvisomant - EMEA/H/C/000409/II/0108/G Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race Opinion adopted on 18.01.2024.	Positive Opinion adopted by consensus on 18.01.2024.
Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0116/G Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 25.01.2024, 14.12.2023.	Request for supplementary information adopted with a specific timetable.
Sugammadex Piramal - Sugammadex - EMEA/H/C/006083/II/0001 Piramal Critical Care B.V., Generic, Generic of Bridion, Rapporteur: Hrefna Gudmundsdottir Opinion adopted on 25.01.2024.	Positive Opinion adopted by consensus on 25.01.2024.

Supemtek - Influenza quadrivalent vaccine (rDNA) - EMEA/H/C/005159/II/0013/G Sanofi Pasteur, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 18.01.2024.	Request for supplementary information adopted with a specific timetable.
Tabrecta - Capmatinib - EMEA/H/C/004845/II/0007/G Novartis Europharm Limited, Rapporteur: Carolina Prieto Fernandez Request for Supplementary Information adopted on 18.01.2024.	Request for supplementary information adopted with a specific timetable.
TEPMETKO - Tepotinib - EMEA/H/C/005524/II/0012 Merck Europe B.V., Rapporteur: Filip Josephson Request for Supplementary Information adopted on 18.01.2024.	Request for supplementary information adopted with a specific timetable.
TEZSPIRE - Tezepelumab - EMEA/H/C/005588/II/0009/G AstraZeneca AB, Rapporteur: Finbarr Leacy Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 12.10.2023.	Positive Opinion adopted by consensus on 11.01.2024.
TRODELVY - Sacituzumab govitecan - EMEA/H/C/005182/II/0029 Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 30.11.2023.	Positive Opinion adopted by consensus on 11.01.2024.
Vaxelis - Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type B conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0136/G MCM Vaccine B.V., Rapporteur: Christophe Focke Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.
XGEVA - Denosumab - EMEA/H/C/002173/II/0082/G Amgen Europe B.V., Rapporteur: Kristina Dunder Opinion adopted on 25.01.2024. Request for Supplementary Information adopted on 14.12.2023, 19.10.2023.	Positive Opinion adopted by consensus on 25.01.2024.
Yellox - Bromfenac - EMEA/H/C/001198/II/0036/G	Request for supplementary information adopted with a specific timetable.

Bausch + Lomb Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher Request for Supplementary Information adopted on 25.01.2024.	
Yselty - Linzagolix choline - EMEA/H/C/005442/II/0009 Theramex Ireland Limited, Rapporteur: Finbarr Leacy Opinion adopted on 18.01.2024. Request for Supplementary Information adopted on 30.11.2023.	Positive Opinion adopted by consensus on 18.01.2024.
Zejula - Niraparib - EMEA/H/C/004249/II/0046/G, Orphan GlaxoSmithKline (Ireland) Limited, Rapporteur: Ingrid Wang Opinion adopted on 25.01.2024. Request for Supplementary Information adopted on 14.12.2023.	Positive Opinion adopted by consensus on 25.01.2024.
Ziextenzo - Pegfilgrastim - EMEA/H/C/004802/II/0030/G Sandoz GmbH, Rapporteur: Christian Gartner Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 23.11.2023.	Positive Opinion adopted by consensus on 11.01.2024.
Zoonotic Influenza Vaccine Seqirus - Zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) - EMEA/H/C/006375/II/0001 Seqirus S.r.l., Informed Consent of Aflunov, Rapporteur: Maria Grazia Evandri Request for Supplementary Information adopted on 25.01.2024.	Request for supplementary information adopted with a specific timetable.
WS2557/G **Infanrix hexa-** **EMEA/H/C/000296/WS2557/0337/G** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.
WS2574 **Nilemdo-** **EMEA/H/C/004958/WS2574/0033** **Nustendi-** **EMEA/H/C/004959/WS2574/0037** Daiichi Sankyo Europe GmbH, Lead Rapporteur: Patrick Vrijlandt Opinion adopted on 25.01.2024. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 25.01.2024.

on 16.11.2023.	
WS2590 Eucreas-EMEA/H/C/000807/WS2590/0103 Galvus-EMEA/H/C/000771/WS2590/0081 Icandra-EMEA/H/C/001050/WS2590/0108 Jalra-EMEA/H/C/001048/WS2590/0084 Xiliarx-EMEA/H/C/001051/WS2590/0082 Zomarist-EMEA/H/C/001049/WS2590/0105 Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder Opinion adopted on 18.01.2024.	Positive Opinion adopted by consensus on 18.01.2024.

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

AREXVY - Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E - EMEA/H/C/006054/II/0004 GlaxoSmithkline Biologicals S.A., Rapporteur: Patrick Vrijlandt, "Update of sections 4.8 and 5.1 of the SmPC in order to include data on persistence of protection over at least 2 RSV seasons following administration of a single dose of Arexvy based on final results from study RSV OA=ADJ-006 (A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose and annual revaccination doses of GSK's RSVPreF3 OA investigational vaccine in adults aged 60 years and above) and RSV OA=ADJ-004 (A phase 3, randomized, open-label, multi-country study to evaluate the immunogenicity, safety, reactogenicity and persistence of a single dose of the RSVPreF3 OA investigational vaccine and different revaccination schedules in adults aged 60 years and above)." Request for Supplementary Information adopted on 25.01.2024.	Request for supplementary information adopted with a specific timetable.
Benlysta - Belimumab - EMEA/H/C/002015/II/0117 GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder, "Update of section 4.4 of the SmPC in order to amend an existing warning and precautions for Progressive multifocal leukoencephalopathy (PML) following the recent	Positive Opinion adopted by consensus on 11.01.2024.

review of the wording in the company Core Safety Datasheet." Opinion adopted on 11.01.2024.	
Benlysta - Belimumab - EMEA/H/C/002015/II/0118 GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to change the frequency of urticaria and rash from uncommon to common and to change the frequency of diarrhoea and nausea from very common to common and to update the Summary of the safety profile based on a cumulative review of clinical trials. The Package Leaflet is updated accordingly. In addition, the MAH took this opportunity to introduce editorial changes." Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.
BIMERVAX - Selvacovatein - EMEA/H/C/006058/II/0006 Hipra Human Health S.L., Rapporteur: Beata Maria Jakline Ullrich, "Submission of the final report from study HAN-01 listed as a category 3 study in the EU-RMP. This is a phase IIb, randomised, controlled, observer-blinded study to evaluate safety and immunogenicity of a recombinant protein RBD fusion dimer candidate vaccine (PHH-1V) against SARS-CoV-2 in adult healthy volunteers." Opinion adopted on 18.01.2024. Request for Supplementary Information adopted on 16.11.2023, 28.09.2023.	Positive Opinion adopted by consensus on 18.01.2024.
Bimzelx - Bimekizumab - EMEA/H/C/005316/II/0025 UCB Pharma S.A., Rapporteur: Finbarr Leacy, "Update of section 5.1 of the SmPC in order to add long-term efficacy data based on the interim results (week 144 data) from study PS0014 listed as a category 3 study in the RMP (MEA/005); this is an ongoing, multicenter, open-label extension (OLE) study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult study participants with moderate to severe plaque PSO who completed 1 of the 3 completed feeder studies (PS0008, PS0009, and PS0013)." Request for Supplementary Information adopted on 25.01.2024.	Request for supplementary information adopted with a specific timetable.
CAMZYOS - Mavacamten -	Request for supplementary information adopted

EMEA/H/C/005457/II/0006 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Patrick Vrijlandt, "Update of section 4.9 of the SmPC in order to include information on the management of mavacamten overdose with administration of activated charcoal, based on final results from study CV027043. This is a single-center, open-label, randomized, parallel-group study to evaluate the effects of co-administration of activated charcoal with sorbitol on the single-dose PK of mavacamten in healthy subjects. In addition, the MAH took the opportunity to introduce minor updates to the PI and to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 25.01.2024.	with a specific timetable.
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0194 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Submission of the final report from study C4591014 listed as a category 3 study in the RMP. This is a retrospective database study to evaluate the effectiveness of COVID-19 BNT162b2 vaccine in a real-world setting." Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.
Dynastat - Parecoxib - EMEA/H/C/000381/II/0088 Pfizer Europe MA EEIG, Duplicate, Duplicate of Xapit (SRD), Rapporteur: Finbarr Leacy, "Update of section 4.4 of the SmPC in order to update skin reactions information based on literature and post-marketing data; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to align the Package Leaflet with the SmPC." Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 09.11.2023.	Positive Opinion adopted by consensus on 11.01.2024.
Edarbi - Azilsartan medoxomil - EMEA/H/C/002293/II/0033/G Takeda Pharma A/S, Rapporteur: Patrick Vrijlandt, "Grouped application comprising two type II variations as follows: - Update of section 4.8 of the SmPC in order to add rhabdomyolysis to the list of adverse drug reactions (ADRs) with frequency Not known	Request for supplementary information adopted with a specific timetable.

based on the cumulative review of MAH safety database and literature. - Update of section 4.8 of the SmPC in order to add arthralgia to the list of adverse drug reactions (ADRs) with frequency Not known based on the cumulative review of MAH safety database and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to introduce editorial changes to the PI." Request for Supplementary Information adopted on 25.01.2024.	
Ervebo - Recombinant vesicular stomatitis virus - Zaire ebolavirus vaccine (live) - EMEA/H/C/004554/II/0034 Merck Sharp & Dohme B.V., Rapporteur: Christophe Focke, "Update of section 5.1 of the SmPC in order to update long-term of immunogenicity information and safety results based on final results from study V920-009 (Partnership for Research on Ebola Vaccines in Liberia). In addition, the MAH took the opportunity to implement editorial changes to the SmPC and to update the list of local representatives in the Package Leaflet." Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 30.11.2023.	Positive Opinion adopted by consensus on 11.01.2024.
Gardasil 9 - Human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) - EMEA/H/C/003852/II/0069 Merck Sharp & Dohme B.V., Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC in order to update long-term effectiveness information based on results from the 4th interim report for study V503-021, listed as a category 3 study in the RMP. This is a registry-based extension of protocol V503-001 in countries with centralized cervical cancer screening infrastructures to evaluate the long-term effectiveness, immunogenicity, and safety of 9vHPV vaccine as administered to 16- to 26-year-old women. In addition, the MAH took the opportunity to introduce minor changes to the PI and to update the list of local representatives in the Package Leaflet."	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 25.01.2024.	
Gazyvaro - Obinutuzumab - EMEA/H/C/002799/II/0054/G, Orphan Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, "Grouped application comprising two variations as follows: C.I.4 - Update of section 4.4 of the SmPC in order to amend the cytokine release syndrome (CRS) statement based on the cumulative review of the MAH safety database, clinical trials and literature. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.3. A.6 - To change the ATC Code of Obinutuzumab from L01XC15 to L01FA03." Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
Imbruvica - Ibrutinib - EMEA/H/C/003791/II/0083 Janssen-Cilag International N.V., Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC following the 24-month extended follow-up from primary analysis data from study CLL3011. This is a randomized, open-label, Phase 3 Study of the combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). In addition, the MAH took the opportunity to add a footnote to the dose modifications table for non-cardiac events in section 4.2 to define the grading systems used for the adverse reactions." Opinion adopted on 25.01.2024.	Positive Opinion adopted by consensus on 25.01.2024.
Jakavi - Ruxolitinib - EMEA/H/C/002464/II/0068 Novartis Europharm Limited, Rapporteur: Filip Josephson, "Update of sections 4.4 and 5.1 of the SmPC in order to add new warnings on 'Major adverse cardiac events (MACE)', 'Thrombosis', and 'Second primary malignancies', following an Art. 20 Class Referral involving JAK inhibitors approved to treat rheumatoid arthritis and to update efficacy information regarding the effects of ruxolitinib in	Request for supplementary information adopted with a specific timetable.

relation to thromboembolic events based on recently published data from MAJIC-PV study (a randomized, controlled open-label study in polycythemia vera (PV)).” Request for Supplementary Information adopted on 25.01.2024, 12.10.2023.	
Kesimpta - Ofatumumab - EMEA/H/C/005410/II/0013/G Novartis Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher, “A grouped application consisting of: Type II (C.I.4): Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on injection-related reactions and to add ‘Hypersensitivity reactions’ to the list of adverse drug reactions (ADRs) with frequency not known. The Package Leaflet is updated accordingly. Type IB (C.I.z): Addition of a statement in the pre-filled syringes (PFS) instructions for use when PFS has been dropped on a hard surface. Type IA (A.6): To change the ATC Code of ofatumumab from L04AA52 to L04AG12. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.” Opinion adopted on 18.01.2024. Request for Supplementary Information adopted on 14.12.2023.	Positive Opinion adopted by consensus on 18.01.2024.
Kisqali - Ribociclib - EMEA/H/C/004213/II/0041/G Novartis Europharm Limited, Rapporteur: Filip Josephson, “Grouped application comprising two type II variations as follows: - Update of section 5.2 of the SmPC in order to update absorption information based on final results from study CLEE011A2117, a Phase I, single center, two-period, two-treatment, open label, randomized crossover study to investigate the absolute bioavailability of a single oral dose of 600 mg of ribociclib relative to an intravenous (i.v.) infusion of 150 mg ribociclib in healthy subjects. - Update of sections 4.2 and 4.5 of the SmPC in order to update the recommended dose modification when ribociclib is administered in combination with CYP3A4 inhibitors and update the drug-drug interaction information on substances that may increase ribociclib plasma concentrations based on the updated PBPK	Request for supplementary information adopted with a specific timetable.

modelling. In addition, the MAH took this opportunity to introduce minor editorial changes to the Package Leaflet." Request for Supplementary Information adopted on 25.01.2024, 12.10.2023, 22.06.2023.	
LIVMARLI - Maralixibat - EMEA/H/C/005857/II/0009, Orphan Mirum Pharmaceuticals International B.V., Rapporteur: Martina Weise, "Update of section 5.3 of the SmPC in order to update preclinical safety information based on final results from study MRX-NC-006, listed as a category 3 study in the RMP. This is a 104-week oral gavage carcinogenicity study of maralixibat in Sprague Dawley Rats performed to evaluate the toxicity and carcinogenic potential of maralixibat." Opinion adopted on 18.01.2024.	Positive Opinion adopted by consensus on 18.01.2024.
Paxlovid - Nirmatrelvir / Ritonavir - EMEA/H/C/005973/II/0051/G Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Grouped application comprising of the following variations: Type II (C.I.4): Update of section 4.2 of the SmPC in order to add clarifying language to the posology section to distinguish between symptom severity and baseline disease severity. Type II (C.I.4): Update of section 4.4 of the SmPC in order to add information on severe, life-threatening, and fatal drug reactions associated with DDIs. Type II (C.I.4): Update of section 4.6 of the SmPC in order to clarify that there is limited human data on the use of Paxlovid during pregnancy. Type II (C.I.4): Update of section 5.1 of the SmPC in order to update information on antiviral activity." Request for Supplementary Information adopted on 25.01.2024.	Request for supplementary information adopted with a specific timetable.
PONVORY - Ponesimod - EMEA/H/C/005163/II/0013 Janssen-Cilag International N.V., Rapporteur: Peter Mol, "Update of section 4.4 of the SmPC to amend an existing warning on PML-IRIS based on the cumulative review of literature. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, to introduce editorial changes	Request for supplementary information adopted with a specific timetable.

to the PI and to bring the PI in line with the latest QRD template version 10.3." Request for Supplementary Information adopted on 25.01.2024.	
Ronapreve - Casirivimab / Imdevimab - EMEA/H/C/005814/II/0014 Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus, "Submission of the final report from study R10933-10987-COV-2118 (COV-2118) - A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered with Casirivimab+Imdevimab in Healthy Adult Volunteers." Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
SARCLISA - Isatuximab - EMEA/H/C/004977/II/0025 Sanofi Winthrop Industrie, Rapporteur: Peter Mol, "Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to amend an existing warning on second primary malignancies and to update efficacy and safety information based on Overall Survival analysis from study EFC15246 (IKEMA - Randomized, open label, multicenter study assessing the clinical benefit of isatuximab combined with carfilzomib (Kyprolis) and dexamethasone versus carfilzomib with dexamethasone in patients with relapsed and/or refractory multiple myeloma previously treated with 1 to 3 prior lines). In addition, the MAH took this opportunity to introduce editorial changes to the PI." Request for Supplementary Information adopted on 25.01.2024.	Request for supplementary information adopted with a specific timetable.
Sunlenca - Lenacapavir - EMEA/H/C/005638/II/0013 Gilead Sciences Ireland Unlimited Company, Rapporteur: Filip Josephson, "Update of section 5.3 of the SmPC in order to update non-clinical information based on final results from study TX-200-2046 entitled, "104 Week Subcutaneous Injection Carcinogenicity and Toxicokinetic Study of GS-6207 Administered Every 13 Weeks in Wistar-Han Rats". In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 18.01.2024.	
Ultomiris - Ravulizumab - EMEA/H/C/004954/II/0041 Alexion Europe SAS, Rapporteur: Carolina Prieto Fernandez, "Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update the frequency of adverse reactions and to update pharmacokinetic, efficacy and safety information on PNH based on final results from studies ALXN1210-PNH-304, ALXN1210-PNH-301 (listed as a category 3 study in the RMP), ALXN1210-PNH-201 and ALXN1210-PNH-103. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to align the warning in Annex II and the PI where male patients should not father a child or donate sperm up to eight months after treatment and to introduce editorial changes." Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
Veltassa - Patiromer - EMEA/H/C/004180/II/0034/G Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Jayne Crowe, "Grouped application consisting of three Type II variations (C.I.4): Update of sections 4.2 and 5.1 of the SmPC in order to update efficacy information based on final results from study PAT-CR-302 (Diamond); this is a Phase 3b international, double-blind, placebo-controlled, randomised withdrawal, parallel-group study of patiromer for the management of hyperkalaemia (HK) in patients receiving renin-angiotensin-aldosterone system inhibitors (RAASi) for the treatment of heart failure (HF). In addition, the MAH took the opportunity to implement editorial changes to the SmPC. Update of sections 4.8 and 5.1 of the SmPC in order to update safety information based on a pooled safety database. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to the SmPC. Update of section 4.8 of the SmPC in order to add "Hypersensitivity" to the list of adverse drug reactions (ADRs) with frequency "not known", based on post-marketing data." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 25.01.2024, 14.09.2023.	
Volibris - Ambrisentan - EMEA/H/C/000839/II/0067 GlaxoSmithKline (Ireland) Limited, Rapporteur: Maria Concepcion Prieto Yerro, "To update sections 4.8 and 5.1 of the SmPC following the assessment of Art 46 procedure (EMEA/H/C/000839) based on final results from study AMB114588; this is an open-label, long term extension study for treatment of pulmonary arterial hypertension in paediatric patients aged 8 years up to 18 years who have participated in AMB112529 and in whom continued treatment with ambrisentan is desired. In addition, the MAH took the opportunity to implement minor editorial changes to Annex II and to the Package Leaflet." Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
Wegovy - Semaglutide - EMEA/H/C/005422/II/0018 Novo Nordisk A/S, Rapporteur: Patrick Vrijlandt, "Update of section 4.8 of the SmPC in order to add 'Dysgeusia' to the list of adverse drug reactions (ADRs) with frequency 'Common' based on results from clinical studies, post marketing data and literature. The Package Leaflet is updated accordingly." Opinion adopted on 25.01.2024.	Positive Opinion adopted by consensus on 25.01.2024.
Xevudy - Sotrovimab - EMEA/H/C/005676/II/0024 Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher, "Update of section 5.1 of the SmPC in order to include virology information based on data from various pharmacology studies on the in vitro activity of sotrovimab in a pseudotyped virus assay against the SARS-CoV-2 Omicron XBB.1.16 and XBB.2.3 spike variants (PC-23-0137), the XBB.1.16.1 and XBB.1.5.10 spike variants (PC-23-0151), and Omicron spike variants encoding epitope substitutions (PC-22-0108), as well as data on the in vitro activity of sotrovimab in an authentic virus assay against the SARS-CoV-2 XBB.1.16 variant (PC-23-0146), and the SARS-CoV-2 BA.2.75, BA.4.6 and BQ.1.1 variants (PC-23-0139)." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 11.01.2024.	
Zavicefta - Ceftazidime / Avibactam - EMEA/H/C/004027/II/0033 Pfizer Ireland Pharmaceuticals, Rapporteur: Ingrid Wang, "Update of section 4.8 of the SmPC in order to add 'Kounis syndrome' to the list of adverse drug reactions (ADRs). A warning about this syndrome was also added to section 4.4, with a cross-reference to section 4.8. The Package Leaflet was updated accordingly. In addition, the MAH took the opportunity to introduce minor changes to the PI and to update the list of local representatives in the Package Leaflet." Opinion adopted on 25.01.2024. Request for Supplementary Information adopted on 09.11.2023.	Positive Opinion adopted by consensus on 25.01.2024.
Zinforo - Ceftaroline fosamil - EMEA/H/C/002252/II/0063 Pfizer Ireland Pharmaceuticals, Rapporteur: Alar Irs, "Update of section 4.8 of the SmPC in order to add 'Kounis Syndrome' to the list of adverse drug reactions (ADRs). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor changes to the PI and to update the list of local representatives in the Package Leaflet." Opinion adopted on 25.01.2024. Request for Supplementary Information adopted on 30.11.2023.	Positive Opinion adopted by consensus on 25.01.2024.
WS2502 **CoAprovel- EMEA/H/C/000222/WS2502/0214** **Karvezide- EMEA/H/C/000221/WS2502/0214** Sanofi Winthrop Industrie, Lead Rapporteur: Maria Concepcion Prieto Yerro, "Update of section 5.3 of the SmPC in order to update information on hydrochlorothiazide monocomponent based on literature review." Opinion adopted on 25.01.2024. Request for Supplementary Information adopted on 23.11.2023.	Positive Opinion adopted by consensus on 25.01.2024.
WS2520/G **Lyrica- EMEA/H/C/000546/WS2520/0124/G** **Pregabalin Pfizer- EMEA/H/C/003880/WS2520/0052/G**	Request for supplementary information adopted with a specific timetable.

Upjohn EESV, Lead Rapporteur: Peter Mol, "Grouped application comprising two type II as follows: C.I.4 - Update of sections 4.4 and 5.1 of the SmPC in order to add information on potential abuse in recreational drug users based on final results from study A0081365 "A Phase 4 Randomized Double-Blind Double-Dummy Placebo- and Active-Controlled Single-Dose Six-way Crossover Study Evaluating the Abuse Potential of Lyrica Taken Orally with Oxycodone HCl in Healthy Non-Drug Dependent Recreational Opioid Users". A.6 - To change the ATC Code from N03AX16 to N02BF02." Request for Supplementary Information adopted on 11.01.2024, 31.08.2023.	
WS2573/G **Kinzalkomb-** **EMEA/H/C/000415/WS2573/0122/G** **MicardisPlus-** **EMEA/H/C/000413/WS2573/0129/G** **PritorPlus-** **EMEA/H/C/000414/WS2573/0132/G** Boehringer Ingelheim International GmbH, Lead Rapporteur: Paolo Gasparini, "Grouped application consisting of: C.I.4 (Type II): Update of section 4.8 of the SmPC in accordance with the "Guideline on fixed combination medicinal products, Doc. Ref. CPMP/EWP/240/95 Rev. 1". The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to the SmPC, Labelling and Annex II of the PI, as well as, to update the list of local representatives in the Package Leaflet. Furthermore, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.3. C.I.4 (Type II): Update of sections 4.2, 4.3, 4.4, 4.5 and 5.2 of the SmPC in order to align with reference labels for both active substances. The Package is updated accordingly. C.I.z (type IB unforeseen): Update section 4.7 of the SmPC to replace the term "drowsiness" by "syncope or vertigo" to align it with adverse reactions table in section 4.8 of SmPC. The Package Leaflet is updated accordingly. C.I.3.a (type IAIN): Update section 5.3 of the SmPC based on the EMA request dated 31 Jan	Positive Opinion adopted by consensus on 25.01.2024.

2023 for the HCTZ containing medicinal products to remove the sentence '…the extensive human experience with hydrochlorothiazide has failed to show an association between its use and an increase in neoplasms' in order to address an inconsistency in the PI." Opinion adopted on 25.01.2024. Request for Supplementary Information adopted on 07.12.2023.	
WS2597 **OPDIVO-** **EMEA/H/C/003985/WS2597/0138** **Yervoy-EMEA/H/C/002213/WS2597/0107** Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Carolina Prieto Fernandez, "Update of section 4.8 of the SmPC in order to add 'myelitis' to the list of adverse drug reactions (ADRs) based on post- marketing data and literature; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to the SmPC." Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
WS2603 **Eucreas-** **EMEA/H/C/000807/WS2603/0105** **Galvus-EMEA/H/C/000771/WS2603/0082** **Icandra-** **EMEA/H/C/001050/WS2603/0110** **Jalra-EMEA/H/C/001048/WS2603/0085** **Xiliarx-EMEA/H/C/001051/WS2603/0083** **Zomarist-** **EMEA/H/C/001049/WS2603/0107** Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to add 'Cholecystitis' to the list of adverse drug reactions (ADRs) with frequency 'Not known'. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.

B.5.3. CHMP-PRAC assessed procedures

BIMERVAX - Selvacovatein - **EMEA/H/C/006058/II/0010** Hipra Human Health S.L., Rapporteur: Beata	Request for supplementary information adopted with a specific timetable.

Maria Jakline Ullrich, PRAC Rapporteur: Zane Neikena, "Submission of the final report from study HIPRA-HH-5, "A phase III, open label, single arm, multi-center, trial to assess the safety and immunogenicity of a booster vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) against SARS-COV-2, in adults vaccinated against COVID-19". The RMP version 1.3 has also been submitted." Request for Supplementary Information adopted on 11.01.2024.	
Enhertu - Trastuzumab deruxtecan - EMEA/H/C/005124/II/0040 Daiichi Sankyo Europe GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Carla Torre, "Update of sections 4.2 and 5.2 of the SmPC based on the final results from studies DS8201-A-J101, DS8201-A-J102, DS8201-A-A103, DS8201-A-A104, DS8201-A-U201, DS8201-A-J202, DS8201-A-J203, DS8201-A-U204, DS8201-A-U205, DS8201-A-U206, DS8201-A-U207, DS8201-A-U301, DS8201-A-U302, and DS8201-A-U303, in order to fulfil MEA 002 (a collection of PK and safety data in at least 10 subjects with moderate hepatic impairment from ongoing Phase 2 or 3 clinical studies) listed as a category 3 activity in the RMP. The updated RMP version 8.0 has also been submitted. In addition, the MAH took this opportunity to introduce editorial changes to the SmPC, annex II.D and the Package Leaflet." Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.
Kuvan - Sapropterin - EMEA/H/C/000943/II/0078 BioMarin International Limited, Rapporteur: Jayne Crowe, PRAC Rapporteur: Eamon O Murchu, "Submission of the final report from study KOGNITO, listed as a category 3 study in the RMP. This is a Phase IV Open-Label, Single-Cohort Study of the Long-Term Neurocognitive Outcomes in 4 to 5 Year-Old Children with Phenylketonuria Treated with Sapropterin Dihydrochloride (Kuvan) for 7 Years. The RMP version 16.0 has also been submitted." Request for Supplementary Information adopted on 11.01.2024, 28.09.2023.	Request for supplementary information adopted with a specific timetable.
LUMYKRAS - Sotorasib - EMEA/H/C/005522/II/0007	Positive Opinion adopted by consensus on

Amgen Europe B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Marie Louise Schougaard Christiansen, "Update of sections 4.2 and 5.2 of the SmPC in order to update recommendations for patients with moderate to severe hepatic impairment following final results from study 20200362 listed as a category 3 PASS study in the EU RMP; this is a Phase I clinical study to evaluate the pharmacokinetics (PK) of a single oral dose of sotorasib administered in subjects with moderate or severe hepatic impairment compared with subjects who have normal hepatic function. The EU RMP version 1.0 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.3." Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 26.10.2023, 06.07.2023, 16.03.2023.	11.01.2024.
MenQuadfi - Meningococcal Group A, C, W and Y conjugate vaccine - EMEA/H/C/005084/II/0027 Sanofi Pasteur, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Jean-Michel Dogné, "Submission of the final report from study MET52, listed as a category 3 study in the RMP. This was a Phase III, open-label, randomised, parallel-group, active-controlled, multi-center study to evaluate the immunogenicity and describe the safety of MenACYW conjugate vaccine when administered concomitantly with a Meningococcal Group B vaccine and other routine pediatric vaccines as part of the National Immunisation Schedule in healthy infants and toddlers in the United Kingdom. The RMP version 1.3 has also been submitted." Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
Myozyme - Alglucosidase alfa - EMEA/H/C/000636/II/0094 Sanofi B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Nathalie Gault, "Update of section 4.2 of the SmPC in order to add home infusion upon request by PRAC following the assessment of PSUSA/00000086/202109 I based on a cumulative search of the MAH Global Pharmacovigilance database and literature.	Positive Opinion adopted by consensus on 25.01.2024.

The Package Leaflet and Annex II are updated accordingly. The RMP version 10.0 has also been submitted." Opinion adopted on 25.01.2024. Request for Supplementary Information adopted on 12.10.2023, 26.04.2023.	
Prolia - Denosumab - EMEA/H/C/001120/II/0099 Amgen Europe B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Mari Thorn, "Update of sections 4.4 and 4.8 of the SmPC in order to update a warning regarding hypocalcaemia and to include reports of life-threatening events and fatal cases occurred in the post-marketing setting, particularly in patients with severe renal impairment, receiving dialysis or treatment with other calcium lowering drugs based on the cumulative review of the MAH safety database and literature. The Package Leaflet is updated accordingly. The RMP version 32.0 has also been submitted." Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 26.10.2023.	Positive Opinion adopted by consensus on 11.01.2024.
Spravato - Esketamine - EMEA/H/C/004535/II/0020 Janssen-Cilag International N.V., Rapporteur: Martina Weise, PRAC Rapporteur: Kirsti Villikka, "Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on severe hepatic impairment and to include the long-term safety information based on final results from study 54135419TRD3008 (An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression), listed as a category 3 study in the RMP; This was a multicenter, open-label, long-term extension safety study to evaluate safety, tolerability, and efficacy of esketamine in participants with TRD. The RMP version 5.1 has also been submitted. In addition, the MAH took the opportunity to introduce editorial changes to the PI." Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
Tysabri - Natalizumab - EMEA/H/C/000603/II/0136 Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele	Positive Opinion adopted by consensus on 25.01.2024.

Maurer, "Update of sections 4.2 and 4.4 of the SmPC to modify administration instructions and update educational guidance to enable the subcutaneous formulation to be administered outside a clinical setting by healthcare professionals based on the cumulative review of post-marketing and clinical study data. The Package Leaflet and Annex IID are updated accordingly. The RMP version 30.0 has also been submitted. In addition, the MAH took this opportunity to introduce minor editorial changes." Opinion adopted on 25.01.2024. Request for Supplementary Information adopted on 14.12.2023, 09.11.2023, 20.07.2023.	
Vemlidy - Tenofovir alafenamide - EMEA/H/C/004169/II/0043/G Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Valentina Di Giovanni, "Grouped application consisting of: C.I.13: Submission of the final report from study GS-US-320-0108 listed as category 3 studies in the RMP. This is a Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B. The RMP version 11.0 has also been submitted. C.I.13: Submission of the final report from study GS-US-320-0110 listed as category 3 studies in the RMP. This is a Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B. The RMP version 11.0 has also been submitted." Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 28.09.2023.	Positive Opinion adopted by consensus on 11.01.2024.
Vyvgart - Efgartigimod alfa - EMEA/H/C/005849/II/0014, Orphan Argenx, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Rhea Fitzgerald, "Update of section 4.4 of the SmPC in order to amend an existing warning on infusion reactions and hypersensitivity reactions, and update of section 5.1 of the SmPC to update the mechanism of	Request for supplementary information adopted with a specific timetable.

action of efgartigimod in relation to albumin; based on final results from study ARGX-113-1705 listed a category 3 study in the RMP. This is a long-term, single-arm, open-label, multicenter, phase 3 follow-on study of ARGX-113-1704 to evaluate the safety and tolerability of ARGX-113 in patients with myasthenia gravis having generalized muscle weakness. The RMP version 2.2 has also been submitted." Request for Supplementary Information adopted on 11.01.2024.	
Zeposia - Ozanimod - EMEA/H/C/004835/II/0023 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maria del Pilar Rayon, "Update of sections 4.4 and 5.1 of the SmPC in order to update efficacy and safety information based on the final results from study RPC01-3001, listed as a category 3 study in the RMP. This is a multi-site, open label extension trial of RPC1063 in relapsing multiple sclerosis. The study's main objectives were to characterise the long-term safety and tolerability, and the long-term efficacy of ozanimod in patients with relapsing multiple sclerosis. The RMP version 7.0 has also been submitted." Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
WS2451 Bondronat- EMEA/H/C/000101/WS2451/0090 Bonviva- EMEA/H/C/000501/WS2451/0075 Atnahs Pharma Netherlands B.V., Lead Rapporteur: Thalia Marie Estrup Blicher, Lead PRAC Rapporteur: Karin Erneholm, "Update of section 4.4 of the SmPC to add information regarding the risk of "Atypical fractures of other long bones", and section 4.8 of the SmPC to add "Atypical fractures of long bones other than the femur" as a new ADR with frequency 'not known', based on literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.3. The RMP version 3.3 was agreed during the procedure." Opinion adopted on 25.01.2024. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 25.01.2024.

on 12.10.2023, 12.05.2023.	
WS2609 **Copalia HCT-** **EMEA/H/C/001159/WS2609/0110** **Dafiro HCT-** **EMEA/H/C/001160/WS2609/0112** **Exforge HCT-** **EMEA/H/C/001068/WS2609/0109** Novartis Europharm Limited, Lead Rapporteur: Thalia Marie Estrup Blicher, Lead PRAC Rapporteur: Karin Erneholm, "To add interaction with tacrolimus to section 4.5 of the SmPC following the outcome of the amlodipine/ramipril PSUSA (PSUSA/00000181/201503). The package leaflet was updated accordingly." Opinion adopted on 25.01.2024.	Positive Opinion adopted by consensus on 25.01.2024.
WS2610 **Copalia-EMEA/H/C/000774/WS2610/0132** **Dafiro-EMEA/H/C/000776/WS2610/0136** **Exforge-** **EMEA/H/C/000716/WS2610/0131** Novartis Europharm Limited, Lead Rapporteur: Thalia Marie Estrup Blicher, Lead PRAC Rapporteur: Karin Erneholm, "To add interaction with tacrolimus to section 4.5 of the SmPC following the outcome of the amlodipine/ramipril PSUSA (PSUSA/00000181/201503). The package leaflet was updated accordingly. In addition, the MAH is removing the Adverse Events in section 4.8 of SmPC where "Hypokalaemia, Anorexia, Hypercalcaemia, Hyperlipidaemia and Hyperuricaemia" that had been added in error. The MAH is also including a QRD update to package leaflet section 5 on the expiry of the product." Opinion adopted on 25.01.2024.	Positive Opinion adopted by consensus on 25.01.2024.

B.5.4. PRAC assessed procedures

PRAC Led **Aldurazyme - Laronidase -** **EMEA/H/C/000477/II/0085** Sanofi B.V., PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Alexandre Moreau, "To update section 4.2 of the SmPC in order to modify the administration instructions following the assessment of procedure PSUSA/00001830/202104 based on literature	Positive Opinion adopted by consensus on 25.01.2024.

review. The Package Leaflet is updated accordingly. The RMP version 1.0 has also been submitted." Opinion adopted on 25.01.2024. Request for Supplementary Information adopted on 26.10.2023, 08.06.2023, 09.02.2023.	
PRAC Led **Caelyx pegylated liposomal - Doxorubicin - EMEA/H/C/000089/II/0107** Baxter Holding B.V., PRAC Rapporteur: Eva Jirsová, PRAC-CHMP liaison: Petr Vrbata, "Submission of an updated RMP version 6.1 in order to align to GVP Module V Revision 2 requirements, following a request received within the Assessment Report for procedure EMEA/H/C/PSUSA/00001172/202111." Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 30.11.2023, 28.09.2023.	Positive Opinion adopted by consensus on 11.01.2024.
PRAC Led **Enhertu - Trastuzumab deruxtecan - EMEA/H/C/005124/II/0036** Daiichi Sankyo Europe GmbH, PRAC Rapporteur: Carla Torre, PRAC-CHMP liaison: Bruno Sepodes, "Submission of the final report from study 'EU survey of relevant healthcare professionals on understanding of key risk minimisation measures pertaining to ILD/pneumonitis' listed as a category 3 study in the RMP. This is a non-imposed non-interventional PASS." Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 28.09.2023.	Positive Opinion adopted by consensus on 11.01.2024.
PRAC Led **Eurartesim - Piperaquine tetraphosphate / Artenimol - EMEA/H/C/001199/II/0040/G** Alfasigma S.p.A., PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "C.I.13: Submission of the final report from the effectiveness evaluation survey for Eurartesim (protocol no. 3366) listed as a category 3 study in the RMP. This is a European multi-centre online survey to assess physician understanding of the revised edition of the educational material. Consequential changes to RMP version 16.1 have been implemented. C.I.11.b: Submission of an updated RMP version 16.1 in order to delete "Severe Malaria"	Request for supplementary information adopted with a specific timetable.

from the Missing Information." Request for Supplementary Information adopted on 11.01.2024, 28.09.2023, 08.06.2023.	
PRAC Led **Evrysdi - Risdiplam - EMEA/H/C/005145/II/0020** Roche Registration GmbH, PRAC Rapporteur: Jan Neuhauser, PRAC-CHMP liaison: Daniela Philadelphy, "Submission of an updated RMP version 2.0 in order to remove the important potential risk of retinal toxicity with risdiplam due to the absence of evidence of retinal toxicity based on thorough ophthalmological monitoring in clinical studies to date." Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.
PRAC Led **Instanyl - Fentanyl - EMEA/H/C/000959/II/0082** Takeda Pharma A/S, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final report from study Instanyl-5002 listed as a category 3 study in the RMP. This is a non-interventional PASS study with title "Assessment of the Effectiveness of Updated Educational Materials on Prescribers' Knowledge and Behavior with Respect to Risks Associated with INSTANYL Off-Label Use". The RMP version 20.0 has also been submitted." Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.
PRAC Led **Mosquirix - Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) - EMEA/H/W/002300/II/0077** GlaxoSmithkline Biologicals SA, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Karin Janssen van Doorn, "Submission of the final report from study EPI-MALALARIA-002 VS AME (115055). This is a non-interventional study, designed to estimate the incidence of diseases specified as adverse events of special interest, of other adverse events leading to hospitalisation or death, and of meningitis in infants and young children in sub-Saharan Africa." Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.
PRAC Led	Positive Opinion adopted by consensus on

Myozyme - Alglucosidase alfa - EMEA/H/C/000636/II/0093 Sanofi B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final non-interventional Pompe Registry Report 2022 (MEA024 and MEA025)." Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 26.10.2023, 16.03.2023.	11.01.2024.
PRAC Led **Mysimba - Naltrexone hydrochloride / Bupropion hydrochloride - EMEA/H/C/003687/II/0066** Orexigen Therapeutics Ireland Limited, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of final report from study NB-453, listed as a category 3 study in the RMP. This is a noninterventional qualitative research using online focus groups to assess understanding, attitude and behaviour for usage of the Mysimba Physician Prescribing Checklist (PPC) among physicians in the European Union (EU), following a previous cross-sectional survey that aimed at evaluating the effectiveness of the same PPC (study NB-452). The RMP version 12.10 has also been submitted." Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Nivestim - Filgrastim - EMEA/H/C/001142/II/0074/G** Pfizer Europe MA EEIG, PRAC Rapporteur: Kirsti Villikka, PRAC-CHMP liaison: Outi Mäki-Ikola, "Grouped application consisting of: C.I.13: Submission of the final report from the non-interventional (NI) post-authorization safety study (PASS) ZOB-NIV-1513/C1121008, listed as a category 3 study in the RMP. This is a multinational, multi-centre, prospective, non-interventional, post-authorisation safety study in Healthy Donors (HDs) exposed to nivestim (biosimilar filgrastim) for Haematopoietic Stem Cell (HSC) Mobilisation (NEST). The RMP version 12.2 has also been submitted. C.I.11: Submission of an updated RMP version 12.2 to remove the important potential risk of cytogenetic abnormalities and development of secondary haematologic malignancies from the	Positive Opinion adopted by consensus on 11.01.2024.

list of safety concerns following completion of the category 3 NI PASS study ZOB-NIV-1513/C1121008." Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 30.11.2023.	
PRAC Led **Prolia - Denosumab - EMEA/H/C/001120/II/0100** Amgen Europe B.V., PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final report from the post-marketing observational study 20090522, listed as a category 3 study in the RMP. This is a denosumab global safety assessment among women with postmenopausal osteoporosis (PMO), men with osteoporosis, and men and women who receive Prolia with glucocorticoid exposure in multiple observational databases." Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Reblozyl - Luspatercept - EMEA/H/C/004444/II/0023, Orphan** Bristol-Myers Squibb Pharma EEIG, PRAC Rapporteur: Jo Robays, PRAC-CHMP liaison: Karin Janssen van Doorn, "Submission of the final report from study ACE-536-MDS-005 listed as a category 3 study in the RMP. This is a non-interventional post-authorisation safety study (PASS) to evaluate the effectiveness of the additional risk minimisation measure (aRMM) for Reblozyl among Healthcare Providers (HCPs) in the EU/EEA. Update of section 4.6 of the PI and Annex II.D. The Package Leaflet has been updated accordingly. The RMP version 3.2 has been submitted accordingly." Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 28.09.2023.	Positive Opinion adopted by consensus on 11.01.2024.
PRAC Led **Replagal - Agalsidase alfa - EMEA/H/C/000369/II/0126** Takeda Pharmaceuticals International AG Ireland Branch, PRAC Rapporteur: Liana Martirosyan, PRAC-CHMP liaison: Patrick Vrijlandt, "Submission of the final report from the Fabry Outcome Survey (FOS) registry study. The FOS (Fabry Outcome Survey) was a	Positive Opinion adopted by consensus on 11.01.2024.

prospective, multicenter, observational, open-ended disease registry designed to document the clinical outcome over time of patients with Fabry disease, irrespective of their treatment." Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 06.07.2023.	
PRAC Led **SARCLISA - Isatuximab - EMEA/H/C/004977/II/0024** Sanofi Winthrop Industrie, PRAC Rapporteur: Monica Martinez Redondo, PRAC-CHMP liaison: Carolina Prieto Fernandez, "Submission of the final report from study SARSAC09715, listed as a category 3 study in the RMP. This is a non-interventional survey to evaluate the effectiveness of the isatuximab educational materials to minimise the risk of interference for blood typing (minor antigen) (positive indirect Coombs test). The RMP version 1.3 has also been submitted." Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.
PRAC Led **Stelara - Ustekinumab - EMEA/H/C/000958/II/0100** Janssen-Cilag International N.V., PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Jayne Crowe, "Update of section 4.6 of the SmPC in order to update information on pregnancy based on the final synoptic report from study CNTO1275PSO4037 (OTIS); this is a pregnancy exposure registry for Stelara. The Package Leaflet is updated accordingly. The RMP version 26.2 has also been submitted." Request for Supplementary Information adopted on 11.01.2024, 31.08.2023.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Stelara - Ustekinumab - EMEA/H/C/000958/II/0104** Janssen-Cilag International N.V., PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Jayne Crowe, "Submission of the final report from study RRA-20745 listed as a category 3 study in the RMP. This is an observational post-authorisation safety study (PASS) to describe the safety of ustekinumab and other Crohn's disease treatments in a cohort of patients with Crohn's disease. The RMP version 27.2 has also been submitted."	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 11.01.2024.	
PRAC Led **VPRIV - Velaglucerase alfa - EMEA/H/C/001249/II/0061** Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Update of section 4.4 of the SmPC, based on a review of post-marketing data and literature, to add further information regarding the fact that the development of antibodies to velaglucerase alfa may be associated with infusion-related reactions including allergic-type hypersensitivity reactions, and guidance regarding how to request antibody testing services in the clinical setting. Further, Annex IID of the PI was updated to delete the key elements concerning antibody testing. An updated RMP version 12.2 was agreed during the procedure and the proposal to remove certain risks from the list of safety concerns was endorsed, i.e. risks related to 'Reduced Efficacy due to neutralizing antibodies', 'Use in patients with a history of adverse drug reactions in other Enzyme Replacement Therapies', 'Adverse events during off-label use' and 'Activated partial thromboplastin time'." Opinion adopted on 11.01.2024. Request for Supplementary Information adopted on 28.09.2023, 06.07.2023, 14.04.2023, 09.02.2023.	Positive Opinion adopted by consensus on 11.01.2024.
PRAC Led **WS2577 Kinzalmono- EMEA/H/C/000211/WS2577/0120 Micardis- EMEA/H/C/000209/WS2577/0129 Pritor-EMEA/H/C/000210/WS2577/0133** Boehringer Ingelheim International GmbH, Lead Rapporteur: Paolo Gasparini, Lead PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Paolo Gasparini, "Submission of an updated RMP version 6.1 in order to implement an overall update regarding safety concerns based on literature and post-marketing data; and to adapt the RMP to the current RMP format (Rev 2.0.1), in line with GVP Module V, Revision 2."	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 11.01.2024.	
PRAC Led **WS2591/G** **Hefiya-** **EMEA/H/C/004865/WS2591/0050/G** **Hyrimoz-** **EMEA/H/C/004320/WS2591/0049/G** Sandoz GmbH, Lead Rapporteur: Christian Gartner, Lead PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, "C.I.13: Submission of the final report from study RABBIT. This is a German registry for the long-term observation of therapy with biologics in adult patients with rheumatoid arthritis. C.I.13: Submission of the final report from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). This is a registry to investigate the long-term safety outcomes of psoriasis patients treated with biologic therapy. C.I.13: Submission of the final report from the Inflammatory Bowel Disease Registry (UK-IBD). This registry was used to identify adverse reactions to Hyrimoz in a cohort of inflammatory bowel disease patients managed in a real-world setting." Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.
PRAC Led **WS2604** **Riarify-EMEA/H/C/004836/WS2604/0029** **Trydonis-** **EMEA/H/C/004702/WS2604/0034** Chiesi Farmaceutici S.p.A., Informed Consent of Trimbow, Lead PRAC Rapporteur: Jan Neuhauser, PRAC-CHMP liaison: Christian Gartner, "C.I.11.z - To provide a new version of the RMP for Riarify and Trydonis in order to: -update the post-authorisation exposure data -replace the protocol of the PASS study for study CLI-05993BA1-05 in Annex 3, following its approval via procedure EMEA/H/X/004257/MEA/002.3 for Trimbow (Beclometasone/Formoterol/Glycopyrronium bromide) concluded at PRAC in January 2023." Opinion adopted on 25.01.2024	Positive Opinion adopted by consensus on 25.01.2024.
PRAC Led **WS2611** **Kinzalkomb-**	Request for supplementary information adopted with a specific timetable.

EMEA/H/C/000415/WS2611/0123 MicardisPlus- EMEA/H/C/000413/WS2611/0130 PritorPlus- EMEA/H/C/000414/WS2611/0133 Boehringer Ingelheim International GmbH, Lead PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Paolo Gasparini, "Submission of an updated RMP version 9.1 for MicardisPlus, PritorPlus and Kinzalkomb in order to remove all important identified and potential risks from the list of safety concerns and to adapt the RMP to the current RMP format (Rev 2.0.1), in line with GVP Module V, Revision 2." Request for Supplementary Information adopted on 11.01.2024.	

B.5.5. CHMP-CAT assessed procedures

Alofisel - Darvadstrocel - EMEA/H/C/004258/II/0047/G, Orphan, ATMP Takeda Pharma A/S, Rapporteur: Maria Luttgen, CHMP Coordinator: Kristina Dunder Opinion adopted on 25.01.2024, 19.01.2024.	Positive Opinion adopted by consensus on 25.01.2024.
CARVYKTI - Ciltacabtagene autoleucel - EMEA/H/C/005095/II/0023, Orphan, ATMP Janssen-Cilag International NV, Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus Request for Supplementary Information adopted on 19.01.2024, 06.10.2023.	Request for supplementary information adopted with a specific timetable.
Upstaza - Eladocagene exuparvovec - EMEA/H/C/005352/II/0013, Orphan, ATMP PTC Therapeutics International Limited, Rapporteur: Joseph DeCourcey, CHMP Coordinator: Finbarr Leacy Request for Supplementary Information adopted on 19.01.2024, 08.09.2023.	Request for supplementary information adopted with a specific timetable.
Upstaza - Eladocagene exuparvovec - EMEA/H/C/005352/II/0014/G, Orphan, ATMP PTC Therapeutics International Limited, Rapporteur: Joseph DeCourcey, CHMP Coordinator: Finbarr Leacy, "Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update information on safety and efficacy,	Positive Opinion adopted by consensus on 25.01.2024.

based on final results from studies NTUH-AADC-010 and NTUH-AADC-011. NTUH-AADC-010 is an open-label, single arm, externally controlled trial to evaluate safety, efficacy, pharmacodynamics and immunogenicity of AGIL-AADC in children from 18 months to less than 18 years of age with severe AADC deficiency, while NTUH-AADC-011 is an open-label, single arm, externally controlled trial to evaluate efficacy and safety of AGIL-AADC in children from 18 months to less than 6 years of age with severe AADC deficiency. In addition, sections 4.5, 4.9 and 6.6 of the SmPC are updated in order to provide better clarification and guidance for the medical practice. The Package Leaflet is updated accordingly. The MAH also took the opportunity to update the due date of the final report of study AADC-1602 in the Annex II, considering the 10-year follow up of the last patient in study AADC-011, and to introduce minor editorial changes to the PI." Opinion adopted on 25.01.2024, 19.01.2024. Request for Supplementary Information adopted on 06.10.2023.	
WS2607 **Tecartus-** **EMEA/H/C/005102/WS2607/0039** **Yescarta-** **EMEA/H/C/004480/WS2607/0067** Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus Request for Supplementary Information adopted on 19.01.2024.	Request for supplementary information adopted with a specific timetable.

B.5.6. CHMP-PRAC-CAT assessed procedures

B.5.7. PRAC assessed ATMP procedures

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS2475/G **Revatio-** **EMEA/H/C/000638/WS2475/0109/G** **Viagra-** **EMEA/H/C/000202/WS2475/0121/G** Upjohn EESV, Lead Rapporteur: Patrick Vrijlandt Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.

WS2518/G **Combivir-EMEA/H/C/000190/WS2518/0110/G** **Epivir-EMEA/H/C/000107/WS2518/0127/G** **Kivexa-EMEA/H/C/000581/WS2518/0097/G** **Trizivir-EMEA/H/C/000338/WS2518/0132/G** ViiV Healthcare B.V., Lead Rapporteur: Jean-Michel Race Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
WS2570 **Lantus-EMEA/H/C/000284/WS2570/0131** **Suliqua-EMEA/H/C/004243/WS2570/0036** **Toujeo-EMEA/H/C/000309/WS2570/0126** Sanofi-Aventis Deutschland GmbH, Lead Rapporteur: Patrick Vrijlandt Opinion adopted on 18.01.2024. Request for Supplementary Information adopted on 16.11.2023, 05.10.2023.	Positive Opinion adopted by consensus on 18.01.2024.
WS2572/G **Herceptin-EMEA/H/C/000278/WS2572/0191/G** **MabThera-EMEA/H/C/000165/WS2572/0200/G** Roche Registration GmbH, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 18.01.2024. Request for Supplementary Information adopted on 30.11.2023.	Positive Opinion adopted by consensus on 18.01.2024.
WS2582 **HyQvia-EMEA/H/C/002491/WS2582/0092** **Kiovig-EMEA/H/C/000628/WS2582/0124** Takeda Manufacturing Austria AG, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 18.01.2024. Request for Supplementary Information adopted on 09.11.2023.	Positive Opinion adopted by consensus on 18.01.2024.
WS2584 **HyQvia-EMEA/H/C/002491/WS2584/0094** **Kiovig-EMEA/H/C/000628/WS2584/0125** Takeda Manufacturing Austria AG, Lead Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 11.01.2024.	Request for supplementary information adopted with a specific timetable.
WS2601	Positive Opinion adopted by consensus on

Nuwiq-EMEA/H/C/002813/WS2601/0057 **Vihuma-EMEA/H/C/004459/WS2601/0039** Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 11.01.2024.	11.01.2024.
WS2605 **HyQvia-EMEA/H/C/002491/WS2605/0095** **Kiovig-EMEA/H/C/000628/WS2605/0126** Takeda Manufacturing Austria AG, Lead Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 18.01.2024.	Request for supplementary information adopted with a specific timetable.
WS2606/G **M-M-RvaxPro-EMEA/H/C/000604/WS2606/0122/G** **ProQuad-EMEA/H/C/000622/WS2606/0164/G** Merck Sharp & Dohme B.V., Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.
WS2617 **Blitzima-EMEA/H/C/004723/WS2617/0071** **Truxima-EMEA/H/C/004112/WS2617/0074** Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.
WS2624 **Abseamed-EMEA/H/C/000727/WS2624/0109** **Binocrit-EMEA/H/C/000725/WS2624/0109** **Epoetin alfa Hexal-EMEA/H/C/000726/WS2624/0109** Sandoz GmbH, Lead Rapporteur: Alexandre Moreau Opinion adopted on 11.01.2024.	Positive Opinion adopted by consensus on 11.01.2024.

B.5.9. Information on withdrawn type II variation / WS procedure

Instanyl - Fentanyl - EMEA/H/C/000959/II/0081 Takeda Pharma A/S, Rapporteur: Alexandre Moreau, "Update of section 4.9 of the SmPC in order to add Toxic Leukoencephalopathy as a symptom overdose based on the cumulative	The MAH withdrew the procedure on 17.01.2024.

review of safety databases, clinical trial data and literature. The Package Leaflet is updated accordingly. In addition, the MAH took this opportunity to update the list of local representatives in the Package Leaflet and to introduce editorial changes to the PI." Request for Supplementary Information adopted on 11.01.2024. Withdrawal request submitted on 17.01.2024.	
Maviret - Glecaprevir / Pibrentasvir - EMEA/H/C/004430/II/0056 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Jean-Michel Race, "Update of section 5.1 of the SmPC in order to add a statement regarding concordance of SVR4 and SVR12, based on post-hoc analysis of the data from the Phase 2 and 3 clinical trials." Request for Supplementary Information adopted on 23.11.2023. Withdrawal request submitted on 15.12.2023.	The MAH withdrew the procedure on 15.12.2023.
Ozurdex - Dexamethasone - EMEA/H/C/001140/II/0043/G AbbVie Deutschland GmbH & Co. KG, Rapporteur: Maria Concepcion Prieto Yerro Request for Supplementary Information adopted on 17.11.2022. Withdrawal request submitted on 12.01.2024.	The MAH withdrew the procedure on 12.01.2024.
Puregon - Follitropin beta - EMEA/H/C/000086/II/0128 Organon N.V., Rapporteur: Finbarr Leacy, "Update of section 4.8 of the SmPC in order to add "anaphylactic reactions" to the list of adverse drug reactions (ADRs) with frequency not known, based on post-marketing surveillance data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor changes to the PI and to bring it in line with the latest QRD template." Withdrawal request submitted on 19.12.2023.	The MAH withdrew the procedure on 19.12.2023.
Vaxelis - Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type B conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0137 MCM Vaccine B.V., Rapporteur: Christophe Focke, "Update of section 5.1 of the SmPC in order to add information on rates of predicted	The MAH withdrew the procedure on 21.12.2023.

protection against pertussis, based on a validated model that correlates anti-pertussis antibody levels with protection against pertussis; this is a modelling study that applied the validated Storsaeter-Kohberger model to the pertussis pre-vaccination and post-vaccination ELISA outputs from Phase 3 studies V419-007 and V419-008." Withdrawal request submitted on 21.12.2023.

B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

Repotrectinib - EMEA/H/C/006005 Treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and for solid tumours
Aflibercept - EMEA/H/C/005980 treatment of age-related macular degeneration (AMD) and visual impairment
Dimethyl fumarate - EMEA/H/C/006471 treatment of multiple sclerosis
Dimethyl fumarate - EMEA/H/C/006500 treatment of multiple sclerosis
Eltrombopag - EMEA/H/C/006417 treatment of primary immune thrombocytopenia (ITP), chronic hepatitis C virus (HCV) and acquired severe aplastic anaemia (SAA)
Aflibercept - EMEA/H/C/005899 treatment of age-related macular degeneration (AMD), visual impairment and retinopathy of prematurity (ROP)
Autologous cartilage-derived articular chondrocytes, in-vitro expanded - EMEA/H/C/004594, ATMP repair of symptomatic, localised, full-thickness cartilage defects of the knee joint grade III or IV
In vitro diagnostic medical device - EMEA/H/D/006470 to detect amplification of the HER2/neu gene via quantitative fluorescence in situ hybridization

(FISH) in formalin-fixed, paraffin-embedded human breast cancer and adenocarcinomas of the stomach (including gastroesophageal junction) tissue specimens	
Govorestat - EMEA/H/C/006270, Orphan Advanz Pharma Limited, treatment of adults and children aged 2 years and older with a confirmed diagnosis of classic galactosemia	
Odevixibat - EMEA/H/C/006462 treatment of cholestatic pruritus in Alagille syndrome (ALGS)	
In vitro diagnostic medical device - EMEA/H/D/006454 To detect PD-L1 protein	
Vorasidenib - EMEA/H/C/006284, Orphan Les Laboratoires Servier, treatment of predominantly non-enhancing astrocytoma or oligodendroglioma with a IDH1 R132 mutation or IDH2 R172 mutation	**Accelerated review**
Belzutifan - EMEA/H/C/005636 treatment of adult patients with advanced renal cell carcinoma (RCC) and treatment of adult patients with von Hippel-Lindau (VHL) disease	
Filgrastim - EMEA/H/C/006400 for the reduction in the duration of neutropenia and the incidence of febrile neutropenia	

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

Cerdelga - Eliglustat - EMEA/H/C/003724/X/0036/G, Orphan Sanofi B.V., Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Maria del Pilar Rayon, "Extension application to introduce a new strength (21 mg capsule, hard) grouped with an extension of indication (C.I.6.a) to include treatment of paediatric patients with GD1 who are 6 years and older with a minimum body weight of 15 kg, who have been previously treated with enzyme replacement therapy (ERT), and who are CYP2D6 poor metabolisers (PMs), intermediate metabolisers (IMs) or extensive metabolisers (EMs) for Cerdelga, based on interim results from study EFC13738 (Open label, two cohort (with and without imiglucerase), multicenter study to evaluate	

pharmacokinetics, safety, and efficacy of eliglustat in pediatric patients with Gaucher disease type 1 and type 3). As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 8.0 has also been submitted. In addition, the MAH took this opportunity to introduce editorial changes to the PI."

Jakavi - Ruxolitinib - EMEA/H/C/002464/X/0070/G

Novartis Europharm Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, "Extension application to introduce a new pharmaceutical form associated with a new strength (5 mg/ml oral solution) and a new route of administration (gastric use), indicated for the treatment of Graft versus host disease (GvHD) in patients aged 28 days or older.
The above line extension is grouped with a type II variation:
- C.I.6.a - To include treatment of paediatric patients aged 28 days to less than 18 years old in acute and chronic Graft versus Host Disease for JAKAVI, based on final results from studies REACH4 (CINC424F12201) and REACH5 (Study CINC424G12201). REACH4 is a Phase I/II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric patients with grade II-IV acute graft vs. host disease after allogeneic hematopoietic stem cell transplantation; while REACH5 is a Phase II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric subjects with moderate and severe chronic graft vs. host disease after allogeneic stem cell transplantation (both for oral solution and already approved tablets presentations). As a consequence, sections 4.1,4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance.
The RMP (version 16) is updated in accordance.
In addition, the Marketing Authorisation Holder (MAH) took the opportunity to implement editorial changes to Annex II."

Kevzara - Sarilumab - EMEA/H/C/004254/X/0043/G

Sanofi Winthrop Industrie, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Monica

Martinez Redondo, "Extension application to add a new strength of 175 mg/ml solution for injection in vial, grouped with an extension of indication to include treatment of active polyarticular-course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older for KEVZARA, based on results from study DRI13925; this is a multinational, multi-center, open-label, 2 phase, 3 portions study to describe the PK profile as well as safety and efficacy of sarilumab. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."	

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

Apadamtase alfa - EMEA/H/C/006198, Orphan Takeda Manufacturing Austria AG, treatment of congenital thrombotic thrombocytopenic purpura (cTTP) due to ADAMTS13 deficiency List of Questions adopted on 14.09.2023.	
AMGEVITA - Adalimumab - EMEA/H/C/004212/X/0036/G Amgen Europe B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Mari Thorn, "Extension application to introduce a new strength, 80 mg [0.8 ml (100 mg/ml)] solution for injection, grouped with quality variations. The RMP (version 6.0) is updated in accordance." List of Questions adopted on 12.10.2023.	
Insulin icodec - EMEA/H/C/005978 treatment of diabetes mellitus in adults List of Questions adopted on 14.09.2023.	
Fidanacogene elaparvovec - EMEA/H/C/004774, ATMP indicated for the treatment of severe and moderately severe haemophilia B List of Questions adopted on 08.09.2023.	
Capivasertib - EMEA/H/C/006017 is indicated in combination with fulvestrant for the treatment of adult patients with hormone	

receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0 or 1+, or IHC 2+/ISH-) locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine based regimen
List of Questions adopted on 14.09.2023.

Dasatinib - EMEA/H/C/006251
Indicated for the treatment of chronic myelogenous leukaemia (CML)
List of Questions adopted on 14.09.2023.

Dasiglucagon - EMEA/H/C/006214
treatment of severe hypoglycemia in patients with diabetes
List of Questions adopted on 09.11.2023.

Aztreonam / Avibactam - EMEA/H/C/006113
treatment of complicated Intra-Abdominal Infection (cIAI), complicated Urinary Tract Infection (cUTI), including pyelonephritis, Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), and aerobic Gram-negative infections with limited treatment options
List of Questions adopted on 12.12.2023.

Eribulin - EMEA/H/C/006191
treatment of breast cancer and liposarcoma
List of Questions adopted on 14.09.2023.

Fruquintinib - EMEA/H/C/005979
treatment of metastatic colorectal cancer
List of Questions adopted on 12.10.2023.

In vitro diagnostic medical device - EMEA/H/D/006372
next generation sequencing (NGS) assay for tumor mutation profiling
Request for Supplementary Information adopted on 14.12.2023, 09.11.2023.

Iptacopan - EMEA/H/C/005764, Orphan
Novartis Europharm Limited, treatment of paroxysmal nocturnal haemoglobinuria
List of Questions adopted on 14.09.2023.

Rituximab - EMEA/H/C/006224
treatment of Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukaemia (CLL) and Rheumatoid arthritis
List of Questions adopted on 14.09.2023.

Omalizumab - EMEA/H/C/005958
treatment of asthma
List of Questions adopted on 14.09.2023.

Reagila - Cariprazine - EMEA/H/C/002770/X/0033
Gedeon Richter Plc., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ana Sofia Diniz Martins, "Extension application to introduce a new pharmaceutical form (orodispersible tablets).
The RMP (version 3.0) is updated in accordance."
List of Questions adopted on 09.11.2023.

Rozlytrek - Entrectinib - EMEA/H/C/004936/X/0017/G
Roche Registration GmbH, Rapporteur: Paolo Gasparini, PRAC Rapporteur: Bianca Mulder, "Extension application to:
1) Introduce a new pharmaceutical form (coated granules) associated with a new strength (50 mg).
2) Introduce a new route of administration (gastroenteral use) for the already authorised 100 mg and 200 mg hard capsules presentations.
The above two line extensions are grouped with 3 type II variations:
- C.I.6.a - To extend the currently approved indication in solid tumours with NTRK gene fusion to patients from birth to 12 years of age (both for the coated granules and already approved hard capsules presentations).
- C.I.6.a - To add a new paediatric indication from birth to 18 years of age for patients with solid tumours with a ROS1 gene fusion (both for the coated granules and already approved hard capsules presentations).
Based on final results from studies CO40778 (STARTRK-NG), GO40782 (STARTRK-2) and BO41932 (TAPISTRY). Study CO40778 is a Phase I/II open-label, dose-escalation and expansion study of entrectinib in pediatrics with locally advanced or metastatic solid or primary CNS tumors and/or who have no satisfactory treatment options; study GO40782 is an open-label, multicenter, global Phase II basket study of entrectinib for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene rearrangement (fusion), and study

BO41932 is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay.
As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 6.3, 6.4 and 6.6 of the SmPC are updated accordingly. The Package Leaflet and Labelling are updated in accordance.
- C.I.4 - To add wording regarding the option of suspension in water of the content of the capsules to be used orally or via the e.g., gastric or nasogastric tube (in sections 4.2 and 5.2 of the SmPC).
The RMP (version 5) is updated in accordance.
The MAH took the opportunity to introduce minor editorial changes to the PI and to update Annex II of the SmPC."
List of Questions adopted on 14.09.2023.

rdESAT-6 / rCFP-10 - EMEA/H/C/006177
Diagnosis of infection with Mycobacterium tuberculosis
List of Questions adopted on 22.06.2023.

Ustekinumab - EMEA/H/C/005918
treatment of adult patients with moderately to severely active Crohn's disease and active ulcerative colitis.
List of Questions adopted on 12.10.2023.

Ustekinumab - EMEA/H/C/006415
treatment of moderate to severe plaque psoriasis in adults, children and adolescents, active psoriatic arthritis in adults and Crohn's Disease, treatment of Crohn's Disease
List of Questions adopted on 14.09.2023.

In vitro diagnostic medical device - EMEA/H/D/006341
detection of the anaplastic lymphoma kinase (ALK) protein
Request for Supplementary Information adopted on 14.12.2023.

Vibegron - EMEA/H/C/005957
treatment of micturition frequency and/or

urgency incontinence as may occur in adult patients with Over Active Bladder (OAB) syndrome.
List of Questions adopted on 14.09.2023.

Zolbetuximab - EMEA/H/C/005868, Orphan
Astellas Pharma Europe B.V., treatment of locally advanced unresectable or metastatic HER2 negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma
List of Questions adopted on 09.11.2023.

Ustekinumab - EMEA/H/C/006132
treatment of moderate to severe plaque psoriasis in adults, children and adolescents, active psoriatic arthritis in adults, Crohn's Disease and ulcerative colitis, treatment of Crohn's Disease and Ulcerative colitis
List of Questions adopted on 14.09.2023.

XALKORI - Crizotinib - EMEA/H/C/002489/X/0080/G
Pfizer Europe MA EEIG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "Extension application to introduce a new pharmaceutical form (granules in capsules for opening) associated with new strengths (20, 50 and 150 mg), grouped with a type II variation (C.I.6.a) to include the treatment of paediatric patients with relapsed or refractory, systemic ALK-positive ALCL or unresectable, recurrent, or refractory ALK-positive IMT to change the lower end of the age range from >=6 years to ≥1 year for Xalkori following the assessment of II/0072 based on final results from study ADVL0912. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 9.1 of the RMP has also been submitted."
List of Questions adopted on 12.10.2023.

B.6.4. Annual Re-assessments: timetables for adoption

Defitelio - Defibrotide - EMEA/H/C/002393/S/0064, Orphan
Gentium S.r.l., Rapporteur: Kristina Dunder, PRAC Rapporteur: Mari Thorn

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

Deferasirox Mylan - Deferasirox - EMEA/H/C/005014/R/0013
Mylan Pharmaceuticals Limited, Generic, Generic of EXJADE, Rapporteur: Beata Maria Jakline Ullrich, PRAC Rapporteur: Tiphaine Vaillant

Koselugo - Selumetinib - EMEA/H/C/005244/R/0015, Orphan
AstraZeneca AB, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ulla Wändel Liminga

Lunsumio - Mosunetuzumab - EMEA/H/C/005680/R/0008, Orphan
Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ulla Wändel Liminga

Lytgobi - Futibatinib - EMEA/H/C/005627/R/0003
Taiho Pharma Netherlands B.V., Rapporteur: Peter Mol, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ulla Wändel Liminga

Nuceiva - Botulinum toxin type A - EMEA/H/C/004587/R/0037
Evolus Pharma B.V., Rapporteur: Finbarr Leacy, Co-Rapporteur: Martina Weise, PRAC Rapporteur: Adam Przybylkowski

Pandemic influenza vaccine H5N1 AstraZeneca - Pandemic influenza vaccine (H5N1) (live attenuated, nasal) - EMEA/H/C/003963/R/0071
AstraZeneca AB, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Sonja Hrabcik

Rozlytrek - Entrectinib - EMEA/H/C/004936/R/0020
Roche Registration GmbH, Rapporteur: Paolo Gasparini, PRAC Rapporteur: Bianca Mulder

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

Alecensa - Alectinib - EMEA/H/C/004164/II/0047
Roche Registration GmbH, Rapporteur: Filip

Josephson, PRAC Rapporteur: Jana Lukacisinova, "Extension of indication to include the use of Alecensa as monotherapy in adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) as adjuvant treatment following tumour resection, based on final results from study BO40336 (ALINA), a randomized, active controlled, multicenter, open-label, Phase III study designed to evaluate the efficacy and safety of alectinib compared with platinum-based chemotherapy in the adjuvant setting in patients with completely resected Stage IB (tumors 4 cm) to Stage IIIA ALKpositive NSCLC. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet and to introduce editorial changes to the PI. As part of the application, the MAH is requesting a 1-year extension of the market protection." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)	
Dupixent - Dupilumab - EMEA/H/C/004390/II/0081 Sanofi Winthrop Industrie, Rapporteur: Jan Mueller-Berghaus, "Extension of indication to include treatment of children aged 1 year and older to the already approved eosinophilic esophagitis (EoE) indication for Dupixent based on final results from study R668-EE-1877 (Part A, Part B, and Part A Addendum) - A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients with Active Eosinophilic Esophagitis. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance."	
Fasenra - Benralizumab - EMEA/H/C/004433/II/0052 AstraZeneca AB, Rapporteur: Fátima Ventura (PT) (MNAT with PT for Coordination, PT for Quality, PT for Non-Clinical, EL for Clinical Safety, EL for Clinical Pharmacology, EL for	

Clinical Efficacy), PRAC Rapporteur: David Olsen, "Extension of indication to include treatment of eosinophilic granulomatosis with polyangiitis for Fasenra, based results from study D3253C00001 (Mandara); this was a randomised, double-blind, multicentre, parallel group, active-controlled, non-inferiority study that evaluated the efficacy and safety of benralizumab compared with mepolizumab in treatment of patients with EGPA on corticosteroid therapy with or without stable immunosuppressive therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6.1 of the RMP has also been submitted. In addition, the MAH took this opportunity to introduce editorial changes. As part of the application, the MAH is requesting a 1-year extension of the market protection."
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

IMCIVREE - Setmelanotide - EMEA/H/C/005089/II/0018, Orphan

Rhythm Pharmaceuticals Netherlands B.V., Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Anna Mareková, "Extension of indication to include the population of children aged 2 years and above for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin Type 1 (PCSK1) deficiency or biallelic leptin receptor (LEPR) deficiency and Bardet-Biedl Syndrome (BBS) for IMCIVREE, based on the final results from study RM-493-033 "A Phase 3 Multicenter, One-Year, Open-Label Study of Setmelanotide in Pediatric Patients Aged 2 To <6 Years of Age with Rare Genetic Causes of Obesity"; this is an open label study to evaluate the weight-related parameters along with the safety and tolerability of setmelanotide in patients aged 2 to <6 years. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted. In addition, the MAH took this opportunity to introduce editorial changes to the PI."

Imfinzi - Durvalumab -

EMEA/H/C/004771/II/0064

AstraZeneca AB, Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: David Olsen, "Extension of indication to include IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) NSCLC and no known EGFR mutations or ALK rearrangements for IMFINZI, based on the interim results from study D9106C00001 (AEGEAN); this is a Phase III, double-blind, placebo-controlled, multi-center international study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable stages II and III non-small cell lung cancer. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 11 of the RMP has also been submitted."

Kevzara - Sarilumab - EMEA/H/C/004254/II/0044

Sanofi Winthrop Industrie, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Monica Martinez Redondo, "Extension of indication to include treatment of Polymyalgia Rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper for Kevzara, based on results from study EFC15160; this is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with polymyalgia rheumatica; As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP is also submitted. As part of the application, the MAH is requesting a 1-year extension of the market protection." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Otezla - Apremilast - EMEA/H/C/003746/II/0044/G

Amgen Europe B.V., Rapporteur: Finbarr Leacy, PRAC Rapporteur: Monica Martinez Redondo, "A grouped application of a Type II variation with two Type IA variations, as follows:

Type II (C.I.6.a): Extension of indication to include the treatment of moderate to severe chronic plaque psoriasis in children and adolescents from the age of 6 years who have a contraindication, have an inadequate response, or are intolerant to at least one other systemic therapy or phototherapy for OTEZLA, based on final results from study CC-10004-PPSO-003 as well as results from studies CC-10004-PPSO-001 and CC-10004-PPSO-004. CC-10004-PPSO-003 is a phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of apremilast (CC-10004) in paediatric subjects from 6 through 17 years of age with moderate to severe plaque psoriasis. As a consequence, sections 4.1, 4.2, 4.4 ,4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 15.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial and formatting changes to the PI and to update the list of local representatives in the Package Leaflet.
2 Type IA (B.II.e.5.a.1)

Pravafenix - Fenofibrate / Pravastatin sodium - EMEA/H/C/001243/II/0037

Laboratoires SMB s.a., Rapporteur: Jean-Michel Race, PRAC Rapporteur: Nathalie Gault, "Extension of indication to include treatment of mixed hyperlipidaemia in adult patients while on a treatment with pravastatin 40 mg monotherapy or on another moderate-intensity statin regimen for PRAVAFENIX, based on final results from the non-interventional PASS: POSE (Pravafenix Observational Study in Europe); this is a European, observational, three-year cohort comparative study on the safety of the fixed dose combination pravastatin 40 mg/fenofibrate 160 mg (Pravafenix) versus statin alone in real clinical practice. As a consequence, sections 4.1 and 4.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted."

RYBREVANT - Amivantamab - EMEA/H/C/005454/II/0011

Janssen-Cilag International N.V., Rapporteur: Filip Josephson, Co-Rapporteur: Johanna

Lähteenvuo, PRAC Rapporteur: Gabriele Maurer, "Extension of indication to include amivantamab in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including a third-generation EGFR tyrosine kinase inhibitor (TKI) for RYBREVANT, based on the final results from study 61186372NSC3002 (MARIPOSA 2); this is a randomized, open label, multicenter Phase 3 study that compares efficacy and safety of amivantamab in combination with carboplatin and pemetrexed (ACP) with carboplatin and pemetrexed (CP). The primary objective of the MARIPOSA 2 study is to compare efficacy, as demonstrated by PFS, in participants treated with ACP versus CP alone. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 4.9, 5.1, 5.2, 6.6 and 9 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.2 of the EU RMP has also been submitted. In addition, the marketing authorisation holder (MAH) is requesting an additional year of market protection." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)	
Slenyto - Melatonin - EMEA/H/C/004425/II/0025 RAD Neurim Pharmaceuticals EEC SARL, Rapporteur: Kristina Dunder, Co-Rapporteur: Tomas Radimersky, PRAC Rapporteur: Ana Sofia Diniz Martins, "Extension of indication to include treatment of neurogenetic disorders (e.g., Angelman syndrome, Rett syndrome, Tuberous sclerosis complex and Williams syndrome) for SLENYTO, based on Phase III study NEU_CH_7911, post-marketing data and literature; As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)	

Veklury - Remdesivir -
EMEA/H/C/005622/II/0053/G
Gilead Sciences Ireland UC, Rapporteur: Janet Koenig (DE) (MNAT with DE-BfArM for Non-Clinical, DE-BfArM for Clinical Efficacy, DE-BfArM for Coordination, DE-BfArM for Clinical Safety, DE-BfArM for Clinical Pharmacology, AT for Quality), PRAC Rapporteur: Eva Jirsová, "Grouped application comprising two extensions of indication to include treatment of paediatric patients weighing at least 1.5 kg for VEKLURY, based on final results from study GS-US-540-5823; this is a Phase 2/3 single-arm, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of remdesivir in participants from birth to < 18 years of age with COVID-19. As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.1 of the RMP has also been submitted."

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

Accofil - Filgrastim -
EMEA/H/C/003956/II/0060/G
Accord Healthcare S.L.U., Rapporteur: Outi Mäki-Ikola

Bevespi Aerosphere - Glycopyrronium / Formoterol fumarate dihydrate -
EMEA/H/C/004245/II/0019/G
AstraZeneca AB, Rapporteur: Kristina Dunder

Braftovi - Encorafenib -
EMEA/H/C/004580/II/0035/G
Pierre Fabre Medicament, Rapporteur: Janet Koenig

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) -
EMEA/H/C/005735/II/0202
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) -
EMEA/H/C/005735/II/0205
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

Dovprela - Pretomanid -
EMEA/H/C/005167/II/0020, Orphan

Mylan IRE Healthcare Limited, Rapporteur: Filip Josephson

Elonva - Corifollitropin alfa - EMEA/H/C/001106/II/0067
Organon N.V., Rapporteur: Patrick Vrijlandt

Empliciti - Elotuzumab - EMEA/H/C/003967/II/0037/G
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Peter Mol

Empliciti - Elotuzumab - EMEA/H/C/003967/II/0038/G
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Peter Mol

Enhertu - Trastuzumab deruxtecan - EMEA/H/C/005124/II/0043/G
Daiichi Sankyo Europe GmbH, Rapporteur: Aaron Sosa Mejia

Enrylaze - Crisantaspase - EMEA/H/C/005917/II/0003/G
Jazz Pharmaceuticals Ireland Limited, Rapporteur: Peter Mol

Fasturtec - Rasburicase - EMEA/H/C/000331/II/0069
Sanofi Winthrop Industrie, Rapporteur: Peter Mol

Hizentra - Human normal immunoglobulin - EMEA/H/C/002127/II/0150/G
CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus

Insuman - Insulin human - EMEA/H/C/000201/II/0146
Sanofi-Aventis Deutschland GmbH, Rapporteur: Karin Janssen van Doorn

Kanuma - Sebelipase alfa - EMEA/H/C/004004/II/0048, Orphan
Alexion Europe SAS, Rapporteur: Karin Janssen van Doorn

Keytruda - Pembrolizumab - EMEA/H/C/003820/II/0149
Merck Sharp & Dohme B.V., Rapporteur: Paolo Gasparini

Kisqali - Ribociclib - EMEA/H/C/004213/II/0048/G
Novartis Europharm Limited, Rapporteur: Filip

Josephson

Klisyri - Tirbanibulin -
EMEA/H/C/005183/II/0014/G
Almirall, S.A., Rapporteur: Finbarr Leacy

Kovaltry - Octocog alfa -
EMEA/H/C/003825/II/0044/G
Bayer AG, Rapporteur: Kristina Dunder

Pemetrexed Accord - Pemetrexed -
EMEA/H/C/004072/II/0028
Accord Healthcare S.L.U., Generic, Generic of Alimta, Rapporteur: John Joseph Borg

Qarziba - Dinutuximab beta -
EMEA/H/C/003918/II/0056/G, Orphan
Recordati Netherlands B.V., Rapporteur: Peter Mol

Reblozyl - Luspatercept -
EMEA/H/C/004444/II/0027, Orphan
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Daniela Philadelphy

Rotarix - Rotavirus vaccine (live, oral) -
EMEA/H/C/000639/II/0132/G
GlaxoSmithKline Biologicals S.A., Rapporteur: Christophe Focke

Spectrila - Asparaginase -
EMEA/H/C/002661/II/0036
medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Christian Gartner

Sugammadex Mylan - Sugammadex -
EMEA/H/C/005403/II/0010/G
Mylan Ireland Limited, Generic, Generic of Bridion, Rapporteur: Hrefna Gudmundsdottir

TRODELVY - Sacituzumab govitecan -
EMEA/H/C/005182/II/0030/G
Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus

Tysabri - Natalizumab -
EMEA/H/C/000603/II/0141/G
Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus

Vitrolife IVF media - Recombinant human albumin solution -
EMEA/H/D/004693/II/0005
Vitrolife Sweden AB, Rapporteur: Maria Grazia

Evandri

Yargesa - Miglustat -
EMEA/H/C/004016/II/0014
Piramal Critical Care B.V., Generic, Generic of Zavesca, Rapporteur: Daniela Philadelphy

Zebinix - Eslicarbazepine acetate -
EMEA/H/C/000988/II/0089/G
Bial - Portela & Cª, S.A., Rapporteur: Martina Weise

Zometa - Zoledronic acid -
EMEA/H/C/000336/II/0103/G
Phoenix Labs Unlimited Company, Rapporteur: Thalia Marie Estrup Blicher

Zoonotic Influenza Vaccine Seqirus -
Zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) -
EMEA/H/C/006375/II/0001
Seqirus S.r.l., Informed Consent of Aflunov, Rapporteur: Maria Grazia Evandri

WS2596
Infanrix hexa-
EMEA/H/C/000296/WS2596/0341
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2598/G
Ambirix-
EMEA/H/C/000426/WS2598/0131/G
Fendrix-
EMEA/H/C/000550/WS2598/0084/G
Infanrix hexa-
EMEA/H/C/000296/WS2598/0338/G
Twinrix Adult-
EMEA/H/C/000112/WS2598/0166/G
Twinrix Paediatric-
EMEA/H/C/000129/WS2598/0167/G
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2600
Infanrix hexa-
EMEA/H/C/000296/WS2600/0339
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2616/G
Hexacima-
EMEA/H/C/002702/WS2616/0153/G
Hexyon-

EMEA/H/C/002796/WS2616/0157/G
Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus

WS2630
Hefiya-EMEA/H/C/004865/WS2630/0052
Hyrimoz-EMEA/H/C/004320/WS2630/0051
Sandoz GmbH, Lead Rapporteur: Christian Gartner

WS2638
Luveris-EMEA/H/C/000292/WS2638/0098
Pergoveris-EMEA/H/C/000714/WS2638/0089
Merck Europe B.V., Lead Rapporteur: Thalia Marie Estrup Blicher

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

BIMERVAX - Selvacovatein - EMEA/H/C/006058/II/0013
Hipra Human Health S.L., Rapporteur: Beata Maria Jakline Ullrich, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to change posology recommendations in individuals 16 years of age and older, amend an existing warning on hypersensitivity and anaphylaxis, delete insomnia and back pain from the list of adverse drug reactions (ADRs), change frequency of odynophagia, abdominal pain and injection site hypersensitivity from Uncommon to Rare and update immunogenicity information based on final results from study HIPRA-HH-2 (PART A and PART B) listed as a category 3 study in the RMP; HIPRA-HH-2 was a Phase IIb, double-blind, randomised, active-controlled, multi-centre, non-inferiority trial in adults fully vaccinated against COVID-19. The objective was to assess immunogenicity and safety of a booster vaccination with a recombinant protein RBD fusion heterodimer vaccine candidate (PHH-1V) against SARS-CoV-2 (Part A). An extension to the study was introduced to add a fourth dose as described below (Part B)."

Brukinsa - Zanubrutinib - EMEA/H/C/004978/II/0018
BeiGene Ireland Ltd, Rapporteur: Aaron Sosa Mejia, "Update of sections 4.2 and 4.5 of the SmPC in order to update information with regards to concomitant use of moderate CYP3A

inducers based on final results from the drug-drug interaction study BGB-3111-112; this is a phase 1, open-label, fixed-sequence study to investigate the effect of the moderate CYP3A inducer rifabutin on the pharmacokinetics of zanubrutinib in healthy male subjects."

Cablivi - Caplacizumab - EMEA/H/C/004426/II/0048, Orphan

Ablynx NV, Rapporteur: Filip Josephson, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update efficacy and safety information on paediatric patients based on results from study OBS17325 - Retrospective Data Collection of Pediatric Patients with Immune Thrombotic Thrombocytopenic Purpura (iTTP) Treated with Caplacizumab. The primary objective of this study was to describe the effectiveness and safety of caplacizumab in pediatric patients with iTTP."

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0203

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Update of section 4.8 of the SmPC in order to update the safety information based on interim (6MPD3 in 6mo-12yo) results from study C4591007, listed as a category 3 study in the RMP. This is an interventional "Phase 1, Open-Label Dose-Finding Study to Evaluate Safety, Tolerability, and Immunogenicity and Phase 2/3 Placebo-Controlled, Observer-Blinded Safety, Tolerability, and Immunogenicity Study of a SARS-CoV-2 RNA Vaccine Candidate Against COVID-19 in Healthy Children.""

Cyramza - Ramucirumab - EMEA/H/C/002829/II/0053

Eli Lilly Nederland B.V., Rapporteur: Peter Mol, "Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety data on paediatric patients following the outcome of Article 46 procedure EMEA/H/C/002829/P46/009 and based on results from study J1S-MC-JV02 (JV02). This is a randomized, open-label, phase 1/2 study evaluating ramucirumab in paediatric patients and young adults with relapsed, recurrent, or refractory synovial sarcoma. In addition, the MAH took the opportunity to implement editorial

updates to the SmPC and the Package Leaflet."

Darzalex - Daratumumab - EMEA/H/C/004077/II/0070, Orphan

Janssen-Cilag International N.V., Rapporteur: Aaron Sosa Mejia, "Update of section 5.1 of the SmPC in order to update efficacy information based on the final overall survival analysis results from study MMY3007. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes."

Duavive - Estrogens conjugated / Bazedoxifene - EMEA/H/C/002314/II/0036

Pfizer Europe MA EEIG, Rapporteur: Martina Weise, "Update of section 4.4 of the SmPC in order to update the wording regarding interactions with other medicinal products and to align with the updated CMDh Core SmPC. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.3."

JCOVDEN - COVID-19 Vaccine Janssen (Ad26.COV2.S) - EMEA/H/C/005737/II/0075/G

Janssen-Cilag International N.V., Rapporteur: Christophe Focke, "A grouped application consisting of six Type II variations, as follows:
C.I.4: Update of section 5.1 of the SmPC in order to update efficacy information based on results on updated genomic sequencing data from study VAC31518COV3001 listed as a category 3 study in the RMP. This is a randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy and safety of Ad26.COV2.S for the prevention of SARS-CoV-2-mediated COVID-19 in adults aged 18 years and older. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to section 6.1 of the SmPC and to the Package Leaflet.
C.I.4: Update of section 5.1 of the SmPC in order to update efficacy information based on results on updated genomic sequencing data from study VAC31518COV3009 listed as a category 3 study in the RMP. This is a Phase 3

randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, reactogenicity, and immunogenicity of 2 doses of Ad26.COV2.S for the prevention of SARS-CoV-2-mediated COVID-19 in adults aged 18 years and older. C.I.13: Submission of the final report from VAC31518COV2008 listed as a category 3 study in the RMP. This is a randomized, double- blind, Phase 2 study to evaluate the immunogenicity, reactogenicity and safety of Ad26.COV2.S administered as booster vaccination in adults 18 years of age and older who have previously received primary vaccination with Ad26.COV2.S or BNT162b2. C.I.13: Submission of the final report from the open label phase of study VAC31518COV3001 listed as a category 3 study in the RMP. C.I.13: Submission of the final report from VAC31518COV4002 listed as a category 3 study in the RMP. This is an observational post-authorization study to assess the effectiveness of Ad26.COV2.S for prevention of COVID-19 using real-world data.”	
Jentadueto - Linagliptin / Metformin hydrochloride - EMEA/H/C/002279/II/0070 Boehringer Ingelheim International GmbH, Rapporteur: Patrick Vrijlandt, “Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update information on paediatric population based on final results from study DINAMO 1218-0091; this is a double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety extension period up to 52 weeks, in children and adolescents with type 2 diabetes mellitus. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”	
Kalydeco - Ivacaftor - EMEA/H/C/002494/II/0124 Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Maria Concepcion Prieto Yerro, “Submission of the final report from Post-Authorisation Effectiveness Study (PAES) VX15-	

770-125 listed as a category 3 study in the RMP (ANX/024). This is an observational study to evaluate the long-term effectiveness and safety of kalydeco in children with cystic fibrosis who have a specified CFTR gating mutation and are aged 2 through 5 years at therapy initiation."

Leqvio - Inclisiran - EMEA/H/C/005333/II/0022

Novartis Europharm Limited, Rapporteur: Martina Weise, "Update of the Package Leaflet (Annex III.B) in order to include complete Instructions For Use for Healthcare Professionals for the pre-filled syringe without needle guard and to update the Instructions For Use for Healthcare Professionals for the pre-filled syringe with needle guard."

Myozyme - Alglucosidase alfa - EMEA/H/C/000636/II/0098

Sanofi B.V., Rapporteur: Alexandre Moreau, "To update section 4.8 of the SmPC to add burning sensation, syncope and asthma to the list of adverse drug reactions (ADRs) with frequency common, not known and not known respectively, following the assessment of procedure II/93 based on the cumulative review of clinical studies, MAH safety database and literature search. The Package Leaflet is updated accordingly."

Orladeyo - Berotralstat - EMEA/H/C/005138/II/0017/G

BioCryst Ireland Limited, Rapporteur: Finbarr Leacy, "A grouped application comprised of two type II variations, as follows:
C.I.4: Update of section 4.5 of the SmPC in order to remove the recommendation for close monitoring for adverse events with concomitant use of P-gp and BCRP inhibitors based on final safety results from the drug-drug interaction study BCX7353-119, as well as to update the effects of cyclosporine on berotralstat. Study BCX7353-119 is a phase 1 drug-drug interaction study to evaluate the effect of cyclosporine on the pharmacokinetics of berotralstat in healthy subjects.
C.I.13: Submission of the final reports from parts 2 and 3 of study BCX7353-301; this is a phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of two dose levels of

BCX7353 as an oral treatment for the suppression of events in subjects with hereditary angioedema.
In addition, the MAH took the opportunity to add additional wording for patients with severely reduced kidney function in the Package Leaflet and to introduce minor editorial changes to the PI, as per previous guidance."

Repatha - Evolocumab - EMEA/H/C/003766/II/0069
Amgen Europe B.V., Rapporteur: Patrick Vrijlandt, "Update of section 5.1 of the SmPC to include Real World Data information based on final results from study 20130296; this is an observational study to describe the clinical characteristics of patients on initiation of Repatha, with a secondary objective to describe the treatment patterns of Repatha use over time."

RINVOQ - Upadacitinib - EMEA/H/C/004760/II/0049
AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC in order to include long-term efficacy and safety information (up to week 104 data) from study M19-944 (study 2); this is a phase 3, randomized, double-blind study evaluating the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with nr-axSpA who completed the double-blind period on study drug."

Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0121/G
Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, "A grouped application consisting of three Type II variations, as follows:
C.I.4: Update of sections 4.5, 4.8 and 5.1 of the SmPC to add drug-drug interaction information of Co-administration of Spikevax (mRNA-1273), including its variant formulations with herpes zoster (shingles) vaccine, based on final results from Clinical Study 217670 (NCT05047770). This is a phase 3, randomized, open-label, controlled, multi-center clinical study to evaluate the immune response and safety of both herpes zoster subunit vaccine (HZ/su or Shingrix) in healthy adults aged 50 years and

older, and the quadrivalent seasonal influenza vaccine (Flu D-QIV or Fluarix Quadrivalent) in healthy adults aged 18 years and older, when administered sequentially or co-administered with mRNA-1273 booster vaccination. C.I.4: Update of sections 4.5, 4.8 and 5.1 of the SmPC to add drug-drug interaction information of Co-administration of Spikevax (mRNA-1273), including its variant formulations with influenza vaccines (standard), based on final results from clinical study 217670 (NCT05047770). This is a phase 3, randomized, open-label, controlled, multi-center clinical study, sponsored by GlaxoSmithKline Biologicals, to evaluate the immune response and safety of both herpes zoster subunit vaccine (HZ/su or Shingrix) in healthy adults aged 50 years and older, and the quadrivalent seasonal influenza vaccine (Flu D-QIV or Fluarix Quadrivalent) in healthy adults aged 18 years and older, when administered sequentially or co-administered with mRNA-1273 booster vaccination. C.I.4: Update of sections 4.5, 4.8 and 5.1 of the SmPC to add drug-drug interaction information of Co-administration of the variants of Spikevax (mRNA-1273) with influenza (high-dose) vaccines, based on final results from clinical study QHD00028 (NCT04969276). This is a Phase II, open-label study, to 'Assess the Safety and Immunogenicity of Fluzone High-Dose Quadrivalent (Influenza Vaccine), 2021-2022 Formulation and a Third Dose of Moderna COVID-19 Vaccine (mRNA-1273 Vaccine) Administered Either Concomitantly or Singly in Adults 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine'."	
Tevimbra - Tislelizumab - EMEA/H/C/005919/II/0002 Novartis Europharm Limited, Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.4 and 4.8 of the SmPC in order to update an existing warning and add 'Stevens-Johnson Syndrome (SJS)' and 'Toxic epidermal necrolysis (TEN)' to the list of adverse drug reactions (ADRs). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."	
Trumenba - Meningococcal group B vaccine	

(recombinant, adsorbed) - EMEA/H/C/004051/II/0052

Pfizer Europe MA EEIG, Rapporteur: Patrick Vrijlandt, "Update of sections 4.2 and 4.8 of the SmPC in order to add information regarding fever in infants 2 months of age based on final results from study C3511002; this is a Phase 2b trial to assess the safety, tolerability, and immunogenicity of MenABCWY in healthy infants 2 and 6 months of age. In addition, the MAH is taking this opportunity to implement a minor editorial update to SmPC section 4.4 to add a 'Traceability' subheading, in line with the QRD product information template version 10.3. Furthermore, as suggested in the linguistic review phase of variation procedure EMEA/H/C/004051/II/0037, the MAH is adding an 'Excipients' subheading to SmPC Section 4.4."

Ultomiris - Ravulizumab - EMEA/H/C/004954/II/0043/G

Alexion Europe SAS, Rapporteur: Carolina Prieto Fernandez, "A grouped application comprised of a Type II variation and a Type IA variation, as follows:
Type II (C.I.4): Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to update clinical information regarding the atypical haemolytic uremic syndrome (aHUS) indication, based on final results from studies ALXN1210-aHUS-311 and ALXN1210-aHUS-312. ALXN1210-aHUS-311 is a phase 3, open-label, uncontrolled, multicenter, single treatment arm study in adolescent and adult patients with evidence of TMA who are naïve to complement inhibitor treatment, while ALXN1210- aHUS-312 is a phase 3, open-label, uncontrolled, multicenter, single treatment arm study in pediatric patients with evidence of TMA who are naïve to complement inhibitor treatment (Cohort 1) or are clinically stable after having been treated with eculizumab (Cohort 2). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.
Type IA (A.6): To change the ATC Code for ravulizumab from L04AA43 to L04AJ02."

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -

EMEA/H/C/005675/II/0099
AstraZeneca AB, Rapporteur: Sol Ruiz, "Submission of the final report from study D8111R00017 (COVIDRIVE) listed as a category 3 PAES in the RMP. This is a post-authorisation retrospective cohort study to evaluate the effectiveness of the AZD1222 vaccine to prevent serious COVID-19 infection in conditions of usual care."

Veklury - Remdesivir - EMEA/H/C/005622/II/0054/G
Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Grouped application to update section 5.2 of the SmPC to update pharmacokinetic information based on results from two Population PK study reports, QP-2023-1074 and CTRA-2023-1084. QP-2023-1074 is a population pharmacokinetic analysis of Sulfobutylether-β-cyclodextrin (SBECD) in adults with normal and impaired renal function following remdesivir administration. CTRA-2023-1084 is a population pharmacokinetic analysis for remdesivir and metabolites (GS-704277 and GS-441524) after administration of remdesivir in adults."

Xeljanz - Tofacitinib - EMEA/H/C/004214/II/0059
Pfizer Europe MA EEIG, Rapporteur: Paolo Gasparini, "Update of section 4.4 of the SmPC in order to update serious infections section based on post- marketing data and literature. In addition, the MAH has taken the opportunity to implement changes to improve readability and to update the list of local representatives in the Package Leaflet."

Zeffix - Lamivudine - EMEA/H/C/000242/II/0087
GlaxoSmithKline (Ireland) Limited, Duplicate, Duplicate of Epivir, Rapporteur: Jean-Michel Race, "Update of section 4.4 of the SmPC in order to amend an existing warning on HIV co-infection. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial changes to the PI."

WS2626
Mirapexin-
EMEA/H/C/000134/WS2626/0107
Sifrol-EMEA/H/C/000133/WS2626/0098

Boehringer Ingelheim International GmbH, Lead Rapporteur: Thalia Marie Estrup Blicher, "Update of section 4.8 of the SmPC in order to add 'spontaneous penile erection' to the list of adverse drug reactions (ADRs) with frequency rare, based on the outcome of a cumulative review. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, introduce minor editorial changes to the PI and bring it in line with the updated QRD template version 10.3."

B.6.10. CHMP-PRAC assessed procedures

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0201

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Liana Martirosyan, "Update of sections 4.5, 4.8 and 5.1 of the SmPC in order to update information regarding concomitant vaccine administration with influenza vaccine based on final results from study C4591030 listed as a category 3 study in the RMP. This is an interventional phase 3, randomized, observer-blind trial to evaluate the safety and immunogenicity of BNT162b2 and quadrivalent seasonal influenza vaccine when administered separately or concomitantly in adults 18 to 64 years of age. The Package Leaflet is updated accordingly. The RMP version 11.1 has also been submitted."

Dovprela - Pretomanid - EMEA/H/C/005167/II/0019/G, Orphan

Mylan IRE Healthcare Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Liana Martirosyan, "Grouped application comprising two variations as follows:
Type II (C.I.4) – Update of sections 4.1 and 5.1 of the SmPC in order to rephrase the indication wording to align with the current WHO definitions. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.
Type IB (C.I.11.z) - Submission of an updated RMP version 2.0 in order to align the safety concerns following the assessment of procedure

EMEA/H/C/005167/11/0013."

Fintepla - Fenfluramine - EMEA/H/C/003933/II/0022/G, Orphan

UCB Pharma SA, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, "A grouped application comprised of three Type II variations, as follows:
C.I.4: Update of sections 4.4 and 4.8 of the SmPC in order to modify the list of adverse drug reactions based on a revised safety ADR methodology for Dravet and Lennox-Gastaut syndromes, which includes pooled analyses encompassing studies ZX008-1503 and ZX008-1601 cohort B. The Package Leaflet is updated accordingly.
C.I.4: Update of section 5.1 of the SmPC in order to update clinical efficacy information for Dravet syndrome based on final results from study ZX008-1503 listed as a category 3 study in the RMP. This is an open-label extension trial to assess the long-term safety of ZX008 (fenfluramine hydrochloride) oral solution as an adjunctive therapy in children and young adults with Dravet syndrome.
C.I.4: Update of section 5.1 of the SmPC in order to update clinical efficacy information for Lennox-Gastaut syndrome based on final results from study ZX008-1601 Part 1 cohort B and interim results for study ZX008-1601 Part 2 cohort B. Study 1601 Part 1 was an international, randomized, double-blind, parallel-group, placebo-controlled study in subjects with LGS 2 to 35 years of age, while study 1601 Part 2 is a long-term, open-label, flexible-dose extension for subjects who completed study 1601 Part 1.
The RMP version 3.0 has also been submitted.
In addition, the MAH took the opportunity to introduce minor changes to the Product Information, including to section 4.2 of the SmPC"

Idefirix - Imlifidase - EMEA/H/C/004849/II/0019, Orphan

Hansa Biopharma AB, Rapporteur: Martina Weise, PRAC Rapporteur: Bianca Mulder, "Update of section 5.1 of the SmPC in order to include the description of the final results from PAES study 17-HMedIdeS-14 listed as a specific obligation in the Annex II (SOB/002); this is a

prospective, observational long-term follow-up study of patients treated with imlifidase (IdeS) prior to kidney transplantation. The primary objective of this trial was to evaluate graft survival in patients who have undergone kidney transplantation after imlifidase administration in earlier trials and relates to both safety and efficacy. The RMP version 1.2 has also been submitted. In addition, the MAH took the opportunity to update section E of Annex II and to implement editorial changes to sections 4.4, 4.6 and 9 of the SmPC. Furthermore, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.3."

Ilumetri - Tildrakizumab - EMEA/H/C/004514/II/0054

Almirall S.A, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Adam Przybylkowski, "Update of section 5.1 of the SmPC in order to update clinical and safety information based on long-term results from the extension periods of the pivotal clinical studies MK-3222-010 (A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects with Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)) and MK-3222-011 (A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222 / MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis). The RMP version 1.4 has also been submitted."

IMVANEX - Smallpox vaccine (live modified vaccinia virus Ankara) - EMEA/H/C/002596/II/0100

Bavarian Nordic A/S, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele Maurer, "Update of section 5.1 of the SmPC in order to add vaccine effectiveness data, and the removal of the two open specific obligations (POX-MVA-039 (SOB02) and SEMVAc (SOB03)), based on the IMVANEX vaccine effectiveness data in real-world use during the 2022 monkeypox

outbreak. Consequently, the MAH proposes a switch from exceptional marketing authorisation to full marketing authorisation. The Annex II and Package Leaflet are updated accordingly. The RMP version 10.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Inrebic - Fedratinib - EMEA/H/C/005026/II/0019, Orphan

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Peter Mol, PRAC Rapporteur: Sonja Hrabcik, "Update of sections 4.2 and 5.2 of the SmPC in order to update posology recommendations in patients with severe hepatic impairment and to update pharmacokinetic information based on final results from study FEDR-CP-001 listed as a category 3 study in the RMP; this is a phase 1, open-label, single-dose study to assess the pharmacokinetics, safety, and tolerability of fedratinib in subjects with moderate and severe hepatic impairment compared with healthy subjects. The RMP version 2.0 has also been submitted."

Juluca - Dolutegravir / Rilpivirine - EMEA/H/C/004427/II/0057/G

ViiV Healthcare B.V., Rapporteur: Janet Koenig, PRAC Rapporteur: Nathalie Gault, "Grouped application comprising two type II variations as follows:
C.I.13: Submission of the final report from study 201636 (SWORD 1) listed as a category 3 study in the RMP. This is a phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed.
C.I.13: Submission of the final report from study 201637 (SWORD 2) listed as a category 3 study in the RMP. This is a phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed.
The RMP version 7.0 has also been submitted."

Jyseleca - Filgotinib -

EMEA/H/C/005113/II/0031/G

Galapagos N.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Grouped application comprising two variations as follows:
Type II (C.I.4): Update of sections 4.8 and 5.1 of the SmPC to update the safety mean duration exposure and efficacy information based on final results (up to week 432) from study GLPG0634-CL-205 (DARWIN 3) listed as a category 3 study in the RMP (MEA/009); this is a phase II, open-label, long-term follow-up safety and efficacy study to evaluate the long-term safety and tolerability of filgotinib for the treatment of Rheumatoid Arthritis in patients who received treatment in their parent studies. The RMP version 6.1 has also been submitted.
Type IA (A.6): To change the ATC code for Janus-associated kinase (JAK) inhibitor from L04AA45 filgotinib to L04AF04 filgotinib."

Ondexxya - Andexanet alfa - EMEA/H/C/004108/II/0044

AstraZeneca AB, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Bianca Mulder, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to update the safety and efficacy information based on the final results from study 18-513 (ANNEXA-I), listed as a specific obligation in the Annex II; this is a phase 4 randomised controlled trial to investigate the efficacy and safety of andexanet alfa versus usual care in patients with acute intracranial haemorrhage taking apixaban, rivaroxaban or edoxaban. Consequently, the MAH proposes a switch from conditional marketing authorisation to full marketing authorisation. The Annex II and Package Leaflet are updated accordingly. The updated RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to bring it in line with the latest QRD template version 10.3."

Retsevmo - Selpercatinib - EMEA/H/C/005375/II/0028

Eli Lilly Nederland B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Bianca Mulder, "Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on interim results from study LIBRETTO-

431 (JZJC) listed as a specific obligation in the Annex II (SOB/002); this is a randomized Phase 3 study comparing selpercatinib to platinum-based and pemetrexed therapy with or without pembrolizumab in patients with locally advanced or metastatic, RET-fusion-positive NSCLC. The Package Leaflet is updated accordingly. The RMP version 6.1 has also been submitted. In addition, the MAH took the opportunity to update Annex II."

RoActemra - Tocilizumab - EMEA/H/C/000955/II/0121

Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele Maurer, "Submission of the final report from study ZUMA-8 (PAM). This is a phase 1 multicenter study evaluating the safety and tolerability of KTE-X19 in adult subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. The RMP version 29.0 has also been submitted."

Ronapreve - Casirivimab / Imdevimab - EMEA/H/C/005814/II/0015

Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Ulla Wändel Liminga, "Update of section 4.6 of the SmPC in order to update information on pregnancy based on a comprehensive analysis of the results from the drug pregnancy registry cohort (PDC study GV44373), listed as a category 3 PASS in the RMP, as well as data from clinical studies and post-marketing surveillance. The RMP version 3.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to update the list of local representatives in the Package Leaflet."

SARCLISA - Isatuximab - EMEA/H/C/004977/II/0026

Sanofi Winthrop Industrie, Rapporteur: Peter Mol, PRAC Rapporteur: Monica Martinez Redondo, "Update of sections 4.2, 4.4 and 5.2 of the SmPC based on final results from study TED16414, listed as a category 3 study in the RMP; this is a phase 1b/2 open label, non-randomized, multi center study to evaluate the safety, pharmacokinetics, and preliminary efficacy of isatuximab (SAR650984) in patients awaiting kidney transplantation. The Package

Leaflet is updated accordingly. The RMP version 1.4 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

ZTALMY - Ganaxolone - EMEA/H/C/005825/II/0005, Orphan

Marinus Pharmaceuticals Emerald Limited, Rapporteur: Peter Mol, PRAC Rapporteur: Adam Przybylkowski, "Update of section 4.2 of the SmPC in order to update dosing instructions in severe hepatic impairment based on data from phase I study 1042-IHF-1001. The RMP version 1.3 has also been submitted."

WS2609
Copalia HCT- EMEA/H/C/001159/WS2609/0110
Dafiro HCT- EMEA/H/C/001160/WS2609/0112
Exforge HCT- EMEA/H/C/001068/WS2609/0109

Novartis Europharm Limited, Lead Rapporteur: Thalia Marie Estrup Blicher, Lead PRAC Rapporteur: Karin Erneholm, "To add interaction with tacrolimus to section 4.5 of the SmPC following the outcome of the amlodipine/ramipril PSUSA (PSUSA/00000181/201503). The package leaflet was updated accordingly."

WS2610
Copalia-EMEA/H/C/000774/WS2610/0132
Dafiro-EMEA/H/C/000776/WS2610/0136
Exforge- EMEA/H/C/000716/WS2610/0131

Novartis Europharm Limited, Lead Rapporteur: Thalia Marie Estrup Blicher, Lead PRAC Rapporteur: Karin Erneholm, "To add interaction with tacrolimus to section 4.5 of the SmPC following the outcome of the amlodipine/ramipril PSUSA (PSUSA/00000181/201503). The package leaflet was updated accordingly. In addition, the MAH is removing the Adverse Events in section 4.8 of SmPC where "Hypokalaemia, Anorexia, Hypercalcaemia, Hyperlipidaemia and Hyperuricaemia" that had been added in error.
The MAH is also including a QRD update to package leaflet section 5 on the expiry of the product."

WS2631

Kisplyx-EMEA/H/C/004224/WS2631/0059
Lenvima-
EMEA/H/C/003727/WS2631/0054

Eisai GmbH, Lead Rapporteur: Karin Janssen van Doorn, Lead PRAC Rapporteur: Ulla Wändel Liminga, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC for Kisplyx and sections 4.8 and 5.1 of the SmPC for Lenvima, in order to reflect the results of two completed paediatric clinical studies E7080-G000-216 and E7080-G000-231. Study 231 is a Phase 2, open-label, multicenter basket study to evaluate the antitumor activity and safety of Lenvatinib in children, adolescents, and young adults with relapsed or refractory solid malignancies. Study 216 is a Phase 1/2, multicenter, open-label, single arm study of lenvatinib in combination with everolimus in pediatric subjects (and young adults aged ≤21 years) with relapsed or refractory malignant solid tumors. The Package Leaflet for Kisplyx is updated accordingly. The RMP version 15.3 has also been submitted."

Dengue Tetravalent Vaccine (Live, Attenuated) Takeda-
EMEA/H/W/005362/WS2593/0012
Qdenga-
EMEA/H/C/005155/WS2593/0013

Takeda GmbH, Lead Rapporteur: Sol Ruiz, Lead PRAC Rapporteur: Liana Martirosyan, "Update of section 4.5 of the SmPC in order to add co-administration information with HPV vaccine based on final results from study DEN-308 listed as a category 3 study in the RMP (MEA003/MEA004); this is a Phase 3, open-label, randomized trial to investigate the immunogenicity and safety of the co-administration of a subcutaneous dengue tetravalent vaccine (live, attenuated) (TDV) and an intramuscular recombinant 9-valent human papillomavirus (9vHPV) vaccine in subjects aged ≥9 to <15 years in an endemic country for dengue; the Package Leaflet is updated accordingly. The RMP version 1.1 has also been submitted. In addition, the MAH took this opportunity to introduce editorial changes and to update the text on PSUR submissions in Annex II for Dengue tetravalent vaccine."

B.6.11. PRAC assessed procedures

PRAC Led

Enbrel - Etanercept - EMEA/H/C/000262/II/0254

Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Monica Martinez Redondo, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "Update of section 4.8 of the SmPC in order to update the frequency of Adverse Drug Reaction (ADR) `Glomerulonephritis' from `Not Known' to `Rare' following PSUSA/00010795/202302 procedure, based on available evidence from clinical trials, literature, and post-marketing data. The Package Leaflet is updated accordingly."

PRAC Led

HyQvia - Human normal immunoglobulin - EMEA/H/C/002491/II/0096

Baxalta Innovations GmbH, PRAC Rapporteur: Gabriele Maurer, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Update of sections 4.8 and 5.1 of the SmPC in order to update long-term safety information based on final results from studies 161406 "Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)" listed as category 3 a study in the RMP and 161302 "Non-Interventional Post-Authorization Safety Study on the Long-Term Safety of HyQvia in Subjects Treated with HyQvia". Both studies were non-interventional, prospective, uncontrolled, multicenter, open-label, post-authorisation studies. The RMP version 15.0 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.3, to update the list of local representatives in the Package Leaflet and to introduce minor editorial changes to the PI."

PRAC Led

Nplate - Romiplostim - EMEA/H/C/000942/II/0091

Amgen Europe B.V., PRAC Rapporteur: Monica Martinez Redondo, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "Submission of an updated RMP version 22 in order to include the latest safety information collected until 31 July 2023 (data lock point). The main change consists of removing the neutralizing antibodies

that cross-react with endogeneous thrombopoietin (eTPO)."

PRAC Led
NUVAXOVID - Covid-19 Vaccine (recombinant, adjuvanted) - EMEA/H/C/005808/II/0060
Novavax CZ, a.s., PRAC Rapporteur: Gabriele Maurer, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of an updated RMP version 4.2 after approval of adapted COVID-19 vaccine by new strain, Omicron XBB.1.5."

PRAC Led
SARCLISA - Isatuximab - EMEA/H/C/004977/II/0027
Sanofi Winthrop Industrie, PRAC Rapporteur: Monica Martinez Redondo, PRAC-CHMP liaison: Carolina Prieto Fernandez, "Update of section 4.8 of the SmPC in order to add 'Thrombocytopenia' and 'Anaemia' to the list of adverse drug reactions (ADRs) and to amend the frequency of all remaining ADRs with their appropriate frequencies, following PRAC request in the outcome of the PSUSA procedure PSUSA/00010851/202303."

PRAC Led
TRODELVY - Sacituzumab govitecan - EMEA/H/C/005182/II/0031
Gilead Sciences Ireland UC, PRAC Rapporteur: Bianca Mulder, PRAC-CHMP liaison: Peter Mol, "Submission of an updated RMP version 3.1 in order to propose the removal of safety concerns."

B.6.12. CHMP-CAT assessed procedures

Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/II/0036/G, ATMP
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Paolo Gasparini, "Grouped application comprising two variations as follows:
C.I.4 – Update of sections 4.4 and 4.8 of the SmPC in order to add immune effector cell-associated neurotoxicity syndrome (ICANS) as an adverse drug reaction (ADR) based on the cumulative review of MAH safety database and literature. The Package Leaflet is updated accordingly. In addition, the MAH took this

opportunity to introduce editorial changes.
A.6 – To include the ATC Code L01XL08 in section 5.1 of the SmPC.”

Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/II/0037/G, ATMP
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Paolo Gasparini

Kymriah - Tisagenlecleucel - EMEA/H/C/004090/II/0079/G, Orphan, ATMP
Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang

WS2500
Tecartus- EMEA/H/C/005102/WS2500/0040
Yescarta- EMEA/H/C/004480/WS2500/0068
Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2533
Jentadueto- EMEA/H/C/002279/WS2533/0071
Trajenta- EMEA/H/C/002110/WS2533/0053
Boehringer Ingelheim International GmbH, Lead Rapporteur: Patrick Vrijlandt

WS2588
Mircera-EMEA/H/C/000739/WS2588/0097
NeoRecormon- EMEA/H/C/000116/WS2588/0122
Roche Registration GmbH, Lead Rapporteur: Martina Weise

WS2594/G
Ambirix- EMEA/H/C/000426/WS2594/0132/G
Twinrix Adult-

EMEA/H/C/000112/WS2594/0167/G
Twinrix Paediatric-
EMEA/H/C/000129/WS2594/0168/G
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2595/G
Riltrava Aerosphere-
EMEA/H/C/005311/WS2595/0009/G
Trixeo Aerosphere-
EMEA/H/C/004983/WS2595/0016/G
AstraZeneca AB, Lead Rapporteur: Finbarr Leacy

WS2605
HyQvia-EMEA/H/C/002491/WS2605/0095
Kiovig-EMEA/H/C/000628/WS2605/0126
Takeda Manufacturing Austria AG, Lead Rapporteur: Jan Mueller-Berghaus
Request for Supplementary Information adopted on 18.01.2024.

WS2618
Dengue Tetravalent Vaccine (Live, Attenuated) Takeda-
EMEA/H/W/005362/WS2618/0013
Qdenga-
EMEA/H/C/005155/WS2618/0014
Takeda GmbH, Lead Rapporteur: Sol Ruiz

WS2621/G
Suboxone-
EMEA/H/C/000697/WS2621/0059/G
Indivior Europe Limited, Lead Rapporteur: Janet Koenig

WS2629/G
Eviplera-
EMEA/H/C/002312/WS2629/0115/G
Stribild-
EMEA/H/C/002574/WS2629/0122/G
Truvada-
EMEA/H/C/000594/WS2629/0180/G
Viread-
EMEA/H/C/000419/WS2629/0211/G
Gilead Sciences Ireland UC, Lead Rapporteur: Jean-Michel Race

WS2643
Nuwiq-EMEA/H/C/002813/WS2643/0059
Vihuma-
EMEA/H/C/004459/WS2643/0041
Octapharma AB, Lead Rapporteur: Jan Mueller-

Berghaus

WS2649
Luveris-EMEA/H/C/000292/WS2649/0099
Pergoveris-
EMEA/H/C/000714/WS2649/0090
Merck Europe B.V., Lead Rapporteur: Thalia
Marie Estrup Blicher

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations:

E.1.3. Initial PMF Certification:

E.2. Time Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures	Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

H. ANNEX H - Product Shared Mailboxes – e-mail address